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ABSTRACT 
Respiratory Syncytial Virus (RSV) is an enveloped single stranded RNA pneumovirus in 
the pneumoviridae family that causes bronchiolitis and pneumonia in preterm and term newborns 
and elderly adults resulting in 75,000 to 125,000 hospitalizations of children below 1 year of age 
in the US each year.  
Currently, there are no approved vaccines or effective therapeutic drugs for RSV 
infection, with treatment being solely limited to supportive care. One of the hurdles for 
developing vaccines or effective therapeutic drugs for RSV infection is a clinically relevant 
animal model. Animal models developed to study RSV infection include mice, cotton rats, 
ferrets, non-human primates, cattle, and lambs. Lambs have several biological features that 
closely mimic RSV infection in human infants such as: similarities to human infants in lung 
development, lung structure and airway branching, cellular composition and immune responses, 
and susceptibility to various strains of RSV, including human strains (Long, A2, and Memphis 
Strain 37).  
To utilize the neonatal lamb model for therapeutic and vaccine studies, the viral kinetics 
of human M37 RSV strain was characterized to follow the progressive development of clinical 
signs, lung pathology and inflammatory/immune responses over time that closely resembled 
those of human infants. Once the viral kinetics of M37 were established, ALX-0171, a trivalent 
nanobody targeting the RSV F-protein was evaluated for its therapeutic potential, safety, and 
dose levels in newborn lambs infected with RSV M37. ALX-0171 was well-tolerated in RSV 
infected newborn lambs and exerted a positive effect on RSV-induced lung lesions while 
reducing symptoms of illness.  
ix 
 
 
To determine the clinical response(s) of the therapeutic drugs being tested, the use of 
video recording and surveillance was implemented to better define and correlate clinical signs 
and sickness behavior of RSV to severity of disease in the neonatal lamb model. Overall, clinical 
signs and sickness behavior were confounded by non-RSV clinical signs of tremors and 
lameness in both RSV infected and non-infected groups, as well as bacterial pneumonias in the 
non-infected group. Future lamb studies should make an effort to solely demonstrate RSV 
infection in lambs by identifying and preventing secondary or opportunistic pathogens.   
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CHAPTER 1.    GENERAL INTRODUCTION 
Statement of the Problem  
            Human Respiratory syncytial virus (hRSV) is a common cause of acute lower respiratory 
disease in infants and young children worldwide. It is the most important viral pathogen causing 
acute lower respiratory tract infections (ALRI) in infants younger than 5 years old and it is 
estimated to have resulted in ~3.4 million hospitalizations and ~200,000 deaths worldwide in 
2005 [1]. It is estimated that in the U.S., the cost associated with the hospitalization of RSV 
infection in children under five is about 394 million U.S. dollars [2]. 
            Currently, there are no approved vaccines or effective therapeutic drugs for RSV 
infection, with treatment being solely limited to supportive care. There exists an inhaled 
nucleoside analog (Ribavirin) that is approved for therapeutic use, but which has limited 
treatment efficacy, as well as a monoclonal antibody (Synagis®, palivizumab), but whose use is 
limited to prophylactic application in high risk infants [3]. One of the hurdles for developing 
vaccines or effective therapeutic drugs for RSV infection is a clinically relevant animal model. 
Lambs have several biological features that closely mimic RSV infection in human 
infants, and when infected with human RSV strains, lambs develop mild clinical symptoms 
including fever, tachypnea, and increased expiratory effort and wheeze, as well as mild to 
moderate gross and histologic lesions [4]. These similarities make neonatal lambs a revelavent 
animal model to study human RSV and for the utilization of therapeutic and vaccine studies.  
Specific Aims 
            The goal of these studies was to establish the viral kinetics of human RSV Memphis 
Strain 37 (M37) in the lamb model of RSV infection (Chapter 2).  This set a baseline of more 
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distinct and precise clinical, viral, physiological, and immunological parameters, as well as the 
progression of pathology and lesions in the lamb model and these parameters that closely 
resembles those of that of human infants. Once the viral kinetics of M37 were established, 
therapeutic compounds such as ALX-0171 were tested for their safety, efficacy, and dose levels 
in the challenged RSV neonatal lamb model (Chapter 3).  To determine the clinical response(s) 
of the therapeutic drugs being tested, the use of video recording and surveillance was 
implemented to better define and correlate clinical signs and sickness behavior of RSV to 
severity of disease in the neonatal lamb model (Chapter 4). 
Dissertation Organization 
            The dissertation is organized into five Chapters, with the first Chapter being a general 
introduction and literature review. The second Chapter, Kinetics of Respiratory Syncytial Virus 
(RSV) Memphis Strain 37 (M37) Infection in the Respiratory Tract of Newborn Lambs as an 
RSV Infection Model for Human Infants, was published in the journal PLoS One. The third 
Chapter, Delivery of ALX-0171 by Inhalation Greatly Reduces Respiratory Syncytial Virus 
(RSV) Disease in Newborn Lambs, will be submitted to the Journal of Monoclonal Antibodies. 
The fourth Chapter, Determining Clinical Signs and Sickness Behavior in a Human RSV 
Neonatal Infection Lamb Model, will be submitted to the journal PLoS One. Finally, Chapter 5 is 
the conclusion and summary of the future of the lamb model.  
Literature Review 
Respiratory Syncytial Virus Classication and Morphology  
Human respiratory syncytial virus (hRSV) is classified in the genus Orthopneumovirus of 
the newly created Pneumoviridae family within the order Mononegavirales, standing apart from 
the original Paramyxoviridae family member [5]. In addition, RSV has an envelope with a linear 
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single stranded, non-segmented RNA molecule of negative-polarity of approximately 15.2 kb, 
which has 10 genes that encodes for 11 proteins [6, 7].  
Viral Genome and Protein Function 
            The two major antigenic surface glycoproteins of RSV include the G-protein and F-
protein (fusion) that have a crucial role in viral replication as they are responsible for viral 
binding to the target cell and virus-cell membrane fusion (syncytia formation), respectively [8]. 
The small hydrophobic (SH) protein is the third surface protein of RSV and is believed to be 
involved in the formation of ion channels which increase RSV virulence degree and permeability 
to small compounds [9]. The non-structural proteins, NS1 and NS2, are virulence factors that 
impair interferon secretion-signaling, inhibit apoptosis of infected cells, modulate innate immune 
response and induce sheeding of infected cells into large airways of the lungs, respectively [10, 
11, 12]. The structual proteins that wrap around the RSV genome include nucleoprotein (N), 
phosphoprotein (P), and the large RNA-dependent RNA polymerase (L) that is involved in 
genomic replication [13]. The matrix (M) protein is necessary for the assembly of RSV [14, 15]. 
The M2.1 and M2.2 proteins are responsible for the assembly of the nucleocapsid and 
modulation of the synthesis of genome and anti-genonome, respectively [16].  
The F protein is the most highly conserved and is the major antigenic protein target for the 
neutralizing epitope, which has four antigenic sites (I, II, IV, and site zero (0)) [17]. The F 
protein is synthesized as a precursor F0 that is cleaved by furin like protease that leads to F1 and 
F2 subunits, with the mature protein containing three copies of F1 and F2 polypeptides. The F 
protein also has two conformations, metastable and stable, with the mestable protein having the 
prefusion conformation (PrF) and the stable protein having the postfusion conformation (PoF) 
after infection. Both metastable and stable conformations of the F protein are present in the 
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surface of RSV; however, neutralizing epitope sites targeted with antibodies differ between both 
conformations [18].  
Viral Phylogenetics and hRSV Strains 
            There are two major antigenic groups of human RSV, Type A and B, with the difference 
between both groups being mostly at the G-protein. Type A has been reported to be the most 
virulent and causing severe clinical disease in the hospital setting [8, 9]. However, there are also 
reports that both types A and B are equally as virulent and that both are able to remain 
genetically distinct by infecting slightly different niches within a population, which alteranate 
between seasons of RSV Types A and B [17, 19].  
           Two relevant human RSV stains used to study RSV are M37 and A2. M37 RSV is a wild 
type RSV-A, first isolated from a 4 month old infant [20] and used in human clinical studies [21–
23]. A2, also belongs to group Type A, and is extensively used in research to study the immune 
response to RSV in numerous cell lines and animal models [24-26]. 
Epidemiology and Susceptibility of hRSV 
            Human Respiratory Syncytial Virus (hRSV) is a major cause of respiratory disease in 
infants and young children in the United States and worldwide [1]. This lower respiratory tract 
infection results in hospitalization in about 3% of RSV-infected infants less than 1 year old, and 
in about 0.5% of RSV-infected children aged between 1 and 2 years [27]. Each year, it is 
estimated that RSV causes at least 3.4 million lower respiratory tract infections requiring 
hospitalization and up to 200,000 deaths worldwide in infants less than 5 years of age [1] and in 
approximately 177,000 hospital admissions and 10,000–14,000 deaths per year in the United 
States in the elderly. 
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            Children under the age of 1 are the most susceptible population to RSV. Predisposing 
factors that are associated with the increased risk to severe RSV disese include: premature 
infants, congenital heart disease, chronic lung disease, cystic fibrosis, neurological conditions, 
congenital malformations, Down’s syndrome, and immunocompromised children. It has also 
been reported that pre-existing disease was a predisposing fator for RSV mortality [28].  
Seasonality, Transmission, and Reinfection of hRSV 
           RSV infection is seasonal and annual epidemics occur mostly in the winter months in 
temperate climates, with substantial morbidity and low mortality [29]. RSV is transmitted by 
direct and indirect contact with nasal or oral secretions from an infected individual [30]. Most 
children are infected with RSV by the age of two at least once, and reinfection can be repetitive, 
even within the same outbreak season. Reinfection has been attributed to RSV promoting an 
inefficient, short lasting adaptive immunity [31].  
Clinical Signs of hRSV 
            As a respiratory virus, RSV infection may present as an upper respiratory tract infection 
(including rhinitis, otitis media and pharyngitis), or as a lower respiratory tract infection 
(including acute bronchiolitis or pneumonia) in vulnerable populations such as infants, elderly 
and immunocompromised adults [32].  Clinical signs in infants and in children develop four to 
six days after infection with RSV, and usually subside after one to two weeks [33]. These signs 
vary with severity of disease and range from mild flu-like symptoms (coughing, sneezing, fever, 
and loss of appetite) in 25% to 40% of first-time exposed infants to severe bronchiolitis with or 
without pneumonia (rapid breathing, difficulty breathing, and wheezing) necessitating 
hospitalization in 0.5% to 2% of infants [34]. In very young infants, irritability, decreased 
6 
 
activity, and apnea may be the only symptoms of infection. These clinical symptoms have been 
attributed to both the immune response to RSV, as well as the direct damage to RSV-infected 
bronchiolar epithelium [35, 36]. 
Treatment and Prevention of hRSV 
           Currently, there are no approved vaccines or effective therapeutic drugs for RSV 
infection, with treatment being solely limited to supportive care. In severe RSV infections, the 
only approved antiviral treatment is the nucleoside analog Virazole (ribavirin), which is 
delivered by inhalation. However, due to concerns for potential teratogenicity and minimal 
evidence of benefit it is not recommended for routine use in infants, but may be considered for 
use in select patients with documented, potentially life-threatening RSV infection [37]. In the 
prevention of RSV infections, Palivizumab (Synagis®, MedImmune), a humanized monoclonal 
antibody (IgG) against the F protein of RSV, has been approved for use in high risk infants; 
however, due to high costs associated with palivizumab prophylaxis limitations to its use have 
been introduced by national boards although cost-effectiveness has been proven in certain high-
risk populations [38]. 
Host Innate Immune Response to hRSV 
            The innate immune system is the first line of defense against RSV. However, before the 
innate immune system is activated, there are physical barriers to the virus, such as the 
mucociliary clearance system, which helps remove dust particles and microbial agents out of the 
respiratory system through sneezing and coughing. Also, the microbiota that inhabits the 
mucosal surfaces prevents colonization of harmful bacteria [39]. 
           Physical barriers are not enough to keep persistent microbial invaders from infecting the 
respiratory tract; therefore, the innate immune system responds through non-specific chemical 
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and cellular defense mechanisms. The chemical defense mechanisms against microbial invaders 
include antimicrobial peptides and digestive enzymes produced by the innate immune cells as 
well as the enzymes that compose the complement system [39].  
           Collectins are soluble pattern recognition molecules, which recognize pathogen associated 
molecular patterns (PAMPs) on the surface of microbial agents. Their function is to help 
eliminate microbial invaders by aggregation, opsonization, complement activation, phagocytosis, 
and inhibition of microbial growth. In the lungs there are specific collectins called surfactant 
protein-A (SP-A) and surfactant protein-D (SP-D) that are produced and secreted by type II 
epithelial cells, and to lesser extent Club (Clara cells) [40]. These collectins are reportedly 
reduced during RSV infection, as well as the production of surfactant. SP-A enhances viral 
clearance by binding to the F protein, and both SP-A and SP-D regulate alveolar macrophage 
function and inflammation [41, 42]. Genetic polymorphisms of SP-A and SP-D are associated 
with severity of RSV disease [43].   
           Defensins are another class of antimicrobial peptides that are produced by respiratory 
epithelium, submucosal glands, and inflammatory cells. Humans have two classes of defensins, α 
and β, which neutralize viruses by targeting viral envelopes, glycoproteins, capsids, and inhibit 
viral fusion and post-entry. Defensins also inhibit viral replication and act as chemokines to alter 
the immune response [44, 45]. In RSV infection of human lung epithelilal A549 cells by A2 
RSV strain, Human β defensin 2 (HBD2) was reported to block viral entry by destabilizing the 
viral envelope [46].  
           In humans and animals there is also an oxidative host defense system at the mucosal 
surface level that has microbicidal activity against bacteria and viruses [47, 48]. This oxidative 
host defense system is composed of a dual oxidase (Duox)/lactoperoxidase (LPO) reaction [H2O2 
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+ SCN-  OSCN-] that leads to the production of oxythiocyanate [OSCN-]. Respiratory 
epithelial cells produce thiocyanate (SCN-), as well as hydrogen peroxide (H2O2) via dual 
oxidases, that are transported to the epithelial surface (air surface liquid of the mucus layer) were 
they are catalyzed by LPO, which is produced by submucosal glands, to produce OSCN- [49,-
50]. When SCN- is substituted by Iodide (I-) in the Duox/LPO reaction, hypoiodite (OI-) is 
produced. Unlike OSCN-, OI- has in vitro and in vivo anti-RSV activity [51-52]. In lambs 
challenged with RSV M37 strain, daily administration of potassium iodide (KI) led to decreased 
RSV disease severity [53]. 
           As indicated, Club (Clara) cells are nonciliated bronchiolar epithelilal cells that have 
several roles that include secretion of immunomodulatory substances (CC10), biometabolization 
of xenobiotics, and are progenitor cells for type II pneumocytes and Club (Clara) cells [54, 55]. 
This population of cells is vulnerable in neonates and chronic smokers [56, 57]. Club (Clara) 
cells secrete Clara cell secretory protein (CC10) (also know as CC16, or uteroglobin), which in 
CC10 knock out mice infected with RSV had increased viral persistence and lung inflammation, 
with Th2 cytokines and neutrophil chemokines being elevated, when compared to CC10 wild 
type mice. The role of CC10 regulating the lung inflammatory response was confirmed with the 
restoration of CC10 in knockout mice that had decresed viral persitance, lung inflammation, and 
airway reactivity [54]. CC10 has been reported to be decreased in patients with chronic asthma, 
chronic obstructive pulmonary disease (COPD), and bronchopulmonary dysplasia [54-57]. On 
the one hand, CC10 increases in bronchoalveolar lavage fluid and serum during acute lung 
injury, such as smoke inhalation and with pneumotoxins (naphthalene, 4 ipomeanol, 
chloroethylene) [55]. As indicated, Club (Clara) cells secrete SP-A and SP-D, but also secrete β 
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defensins, β galactoside binding protein, and RSV receptors (e.g. retinoic acid inducible gene-1) 
that influences the inflammatory response [45].  
           If the physical and chemical barriers of the innate immune system do not remove the 
infectious agent, then target cells (epithelial ciliated cells, macrophages, dentritic cells, basal  
cells infected by  hRSV) will initiate an inflammation response upon infection by recognizing 
pattern associated molecular patterns (PAMPs) on the surface of microbial agents through 
pattern recognition receptors such as toll-like receptors (TLRs), nucleotide-binding 
oligomerization domain (NOD)-like receptors, and retinoic acid-inducible gene I (RIG1)-like 
receptors [58, 59, 60]. Pattern recognition receptors that interact with RSV include TLR-2, TLR-
3, TLR-4, TLR-6, and TLR-7, as well as RIG I-like receptors, and NOD-like receptor protein 3/ 
apoptosis-associated speck-like protein containing a caspase recruitment domain (NLRP3/ASC) 
through indirect activation of TLR-2 first. [61-64].  
           These pattern recognition receptors are the first line of defense, and when activated lead to 
an intracellular cascade that activates type I interferons (Type I IFNs), proinflammatory 
cytokines (IL-1, IL-6, IL-18) through NF-ĸβ pathway, and the indirect activation of the 
inflammasome (NLRP3/ASC) through TLR2 activation [61]. The Fusion protein of RSV also 
stimulates the release of NF-ĸβ to activate IL-1β and IL-6 [65]. However, as previously 
mentioned this initial inflammatory response is disrupted by RSV virulence factors, NS1 and 
NS2 proteins that interfere with the secretion of Type III INFs [10, 11, 12, 66, 67]. Also, the 
nucleoprotein of RSV can act as a virulence factor by locating within the membrane of infected 
cells, which has been reported to inhibit T-cell activation [68, 69]. The infection of macrophages 
and dentritic cells can also distrupt the formation of an effective immunological synapse to 
activate T cells [13, 60]. These changes together result in a weak T cell immune response that 
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leads to reduced cytotoxic activity by CD8+ T cells, and a decrease in RSV clearance [66, 67]. 
The humoral response to RSV in infants leads to the production of IgG1 and IgG3 antibodies 
isotypes, which are protective, but not optimal for viral clearance. These antibody isotypes are 
associated with a Th2 immune response [70, 71].  
           Overall, the immune response to human RSV is characterized by an exacerbated 
inflammation response in the airways that is driven by a Th2 (IL-4, IL-5, IL-10, IL-13) and Th17 
(IL-17, IL-21) and a mild Th1 (INF gamma, IL-12) immune response [72]. This inflammation 
response varies with severity as previously mentioned, but ultimately leads to the infiltration of 
bronchioles by neutrophils, eosinophils, and mononcytes that release their contents and cytokines 
and chemokines (IL-6, IL-8, TNF-α, CXCL2, CXCL10, IL-17, etc.) to recruit macrophages and 
dentritic cells, that all together cause damage to lower airways (bronchiolitis) [72]. The 
bronchiolitis along with the increase production of mucous plugs in the airways, results in the 
clinical symptomology described above. 
           Besides causing bronchiolitis, hRSV infection has been associated with arrhythmias, 
myocardial failure, hepatitis in children, and encephalopathies [73-76]. Long term, severe hRSV 
disease in infancy has been reported to be a high risk factor for the development of asthma [77, 
78].  
Advances in Vaccine Development and Therapeutics for hRSV 
           The search for an effective RSV vaccine was initially held back by the formalin 
inactivated RSV vaccine in the 1960’s that led to enhanced disease and the death of two infants 
[79]. Since then, the development of vaccines have focused on live virus, vectored virus, 
attenuated and inactivated subunits of RSV, as well as specific RSV proteins incorporated into 
nanoparticles and bacterial/virus/plant vectors [55, 80]. These new efforts in vaccine 
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development have primarily focused on the subunits of the F protein of RSV, specifically the Ø 
epitope region of the pre fusion conformation, which is the most significant target for antibody 
recognition that has resulted in high levels of neutralizing antibodies [81, 82, 83]. Using the PrF 
F protein for vaccine development has its limitations with this conformation being unstable in the 
presence of trypsin; therefore, the generation of recombinant PrF F proteins has been 
investigated in cotton rats for vaccine development. Cotton rats had no detectable virus loads 
with significant levels of neutralizing antibodies for the PrF F protein when compared to the PoF 
F protein vaccine [82, 83]. Virus vectors such as influenza have also been used to express 
chimeric proteins containing the F protein, which in challenged mice not only provided 
protection from RSV through neutralizing antibodies, but also decreased lung damage and 
secreted antiviral cytokines [84]. Another example of a recombinant prototype vaccine is the 
mycobacterium bovis BCG (rBCG-N-hRSV), which is used as a vector to express the 
nucleoprotein [13]. In mice, the rBCG-N-hRSV vaccine led neutralizing antibodies, Th1 like 
profile, and a decreased RSV pathology. A new approach to vaccines is the use of Virus like-
Particles (VLPs).  There is two protypes for hRSV using VLPs, one for the F and the second for 
the M protein, both of which in mice have shown high neutralizing antibodies and an effective 
antiviral cytokine response [85]. 
           There have been new advancements made in the anti-RSV therapeutic field since the 
release of Virazole (ribavirin) and Palivizumab to treat and prevent hRSV in high risk infants, 
respectively. ALX-0171 is a novel biotherapeutic by Ablynx NV that is composed of a trivalent 
Nanobody that targets the antigenic site II of the F protein of RSV. Antiviral efficacy of ALX-
0171 has been demonstrated in challenged hRSV cotton rats and recently in newborn lambs, 
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were ALX-0171 exerted a positive effect on RSV induced lung lesions and inflammation and 
reduced symptoms of illness [86]. Currently, ALX-0171 is in phase IIb of human clinical trials.  
           Viral fusion inhibitors are another area of antiviral-RSV biotherapeutics that has seen a 
large growth. JNJ-53718678 by Johnson & Johnson is a small molecule fusion inhibitor that 
binds to the F protein in the prefusion conformation. In neonatal lambs, JNJ-53718678 
demostrated antiviral efficacy and reduced lung inflammation [87]. Currently, a clinical trial with 
JNJ-53718678 is being planned to treat hospitalized infants infected with RSV infection [88]. 
JNJ-53718678 is just one example of many viral fusion inhibitors in the pipeline. There are also 
many viral inhibitors for the SH, N, L, and M2-1 proteins [89]. Many other laboratories have on-
going therapeutic compounds often aimed toward inhibiting viral entry and replication such as 
RNA polymerase inhibitors and Fusion inhibitors. 
Animal Models of RSV Infection 
           Different animal models for RSV infection, including non-human primates, calves, lambs, 
mice, guinea pigs, ferrets, hamsters and cotton rats have been described [90, 91]. The cotton rat 
(Sigmodon hispidus) RSV infection model has been successfully used in the development of 
both RSV-IgIV (RespiGam®, MedImmune, Inc., Gaithersburg, MD, USA) and palivizumab and 
findings in the cotton rat for those agents translated well to the clinical setting [92, 93]. The 
cotton rat model also serves as the primary model for the determination of vaccine safety as they 
develop vaccine-enhanced pulmonary disease that reflects what is seen in humans and non-
human primates [18]. However, and although susceptible to RSV infection, cotton rats do not 
exhibit any clinical signs of upper and lower respiratory tract disease or any age-related 
susceptibility to hRSV in contrast to what is seen for human infants [91].  
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Lamb Model for RSV Infection 
            Colostrum-deprived neonatal lambs are highly relevant for the study of RSV infection 
and may serve as a model of RSV infection in human infants due to the natural susceptibility of 
lambs to ovine, bovine and human strains of RSV as well as similarities in disease pathogenesis 
and anatomical, physiological and developmental similarities to that of human infants [94-96]. 
Experimentally, it has been shown that lambs and other ruminants can be infected with human or 
bovine RSV strains and that the infection induces lung lesions that resemble those observed in 
human RSV pathology such as bronchiolitis with epithelial cell necrosis, syncytial cell 
formation, hyperplasia of nearby epithelium and infiltrates of neutrophils with occasional 
macrophages [51, 97-103]. Moreover, RSV infected lambs develop mild to moderate clinical 
symptoms such as expiratory effort, fever, tachypnea, wheeze, malaise and listlessness [97, 51, 
98, 99, 102] and formalin-inactivated RSV vaccination in lambs induces enhanced lesions upon 
RSV infection [104] as observed in infants [79, 105]. 
Clinical Signs and Sickness Behavior in Lambs 
            Clinical signs in lambs infected with RSV can be variable and unpredictable, and there 
interpretation can be confounded by many variables that include: strain of hRSV, experience of 
the interpreter observing clinical signs, handling of lambs, sampling schedule, experience in 
getting respiration and heart rate, unknown side effects of therapeutic drugs, administration of 
anesthetics, and secondary bacterial infections. To add to this list, lambs are herd animals and 
don’t express clear signs of sickness until severe disease is present or near death. 
            Sickness behavior is an adaptive organized immune response that leads to physiological 
and behavioral changes that are manifested in animals commonly as fever, depression, decreased 
lipido, adipsia, anorexia, and decreased grooming and social interaction due to potentially 
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injurious stimuli, such as microbial agents (e.g. virus, bacteria, fungal, parasites) [106-108]. This 
evolved behavioral response helps to conserve energy through lethargy and fatigue and fight 
bacterial and viral infections by increasing body temperature through fever [108].  
Important immune mediators that contribute to the sickness response include 
proinflammatory cytokines IL-1, IL-6, and tumor necrosis factor [106-108].  Together these 
cytokines mediate local, systemic, and central nervous responses during acute and chronic 
infection that leads to sickness behavior [106]. However, with fever and decreased appetite, the 
immune response can be metabolically expensive, and if prolonged animals may succumb to the 
disease, or become susceptible to predation [108]. 
            Sickness behavior can be easily induced and studied in animals with exposure to 
lipopolysaccharide (LPS) endotoxin. For example in rodents, fever, anorexia, and decreased 
activity and grooming are at their highest at increased lipopolysaccharide (LPS) endotoxin doses 
[109]. Therefore, sickness behavior varies with disease severity. This can also be seen in cattle 
with mastitis and bovine respiratory disease, where the sickness behavior was greater for severe 
disease when compared to mild mastitis and bovine respiratory disease [110, 111]. Sickness 
behavior can be used to detect infected animals; however, identifying animals with mild disease 
and subclinical signs may be more challenging [112]. 
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Abstract 
Rationale 
Respiratory syncytial virus (RSV) infection in preterm and newborn infants can result in 
severe bronchiolitis and hospitalization. The lamb lung has several key features conducive to 
modeling RSV infection in human infants, including susceptibility to human strains of RSV such 
as the A2, Long, and Memphis Strain 37 (M37). In this study, the kinetics of M37 infection was 
investigated in newborn lambs in order to better define clinical, viral, physiological, and 
immunological parameters as well as the pathology and lesions. 
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Methods 
Newborn lambs were nebulized with M37 hRSV (6 mL of 1.27 x 10(7) FFU/mL), 
monitored daily for clinical responses, and respiratory tissues were collected from groups of 
lambs at days 1, 3, 4, 6, and 8 post-inoculation for the assessment of viral replication parameters, 
lesions and also cellular, immunologic and inflammatory responses. 
Results 
Lambs had increased expiratory effort (forced expiration) at days 4, 6, and 8 post-
inoculation. Nasal wash lacked RSV titers at day 1, but titers were present at low levels at days 3 
(peak), 4, and 8. Viral titers in bronchoalveolar lavage fluid (BALF) reached a plateau at day 3 
(4.6 Log10 FFU/mL), which was maintained until day 6 (4.83 Log10 FFU/mL), and were 
markedly reduced or absent at day 8. Viral RNA levels (detected by RT-qPCR) in BALF were 
indistinguishable at days 3 (6.22 ± 0.08 Log10 M37 RNA copies/mL; mean ± se) and 4 (6.20 ± 
0.16 Log10 M37 RNA copies/mL; mean ± se) and increased slightly on day 6 (7.15 ± 0.2 Log10 
M37 RNA copies/mL; mean ± se). Viral antigen in lung tissue as detected by 
immunohistochemistry was not seen at day 1, was present at days 3 and 4 before reaching a peak 
by day 6, and was markedly reduced by day 8. Viral antigen was mainly present in airways 
(bronchi, bronchioles) at day 3 and was increasingly present in alveolar cells at days 4 and 6, 
with reduction at day 8. Histopathologic lesions such as bronchitis/bronchiolitis, epithelial 
necrosis and hyperplasia, peribronchial lymphocyte infiltration, and syncytial cells, were 
consistent with those described previously for lambs and infants. 
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Conclusion 
This work demonstrates that M37 hRSV replication in the lower airways of newborn 
lambs is robust with peak replication on day 3 and sustained until day 6. These findings, along 
with the similarities of lamb lung to those of infants in terms of alveolar development, airway 
branching and epithelium, susceptibility to human RSV strains, lesion characteristics 
(bronchiolitis), lung size, clinical parameters, and immunity, further establish the neonatal lamb 
as a model with key features that mimic RSV infection in infants. 
Introduction 
Human Respiratory Syncytial Virus (hRSV) is an enveloped, non-segmented, single 
stranded negative sense RNA pneumovirus of the paramyxoviridae family that causes lower 
airway respiratory disease in preterm newborns, term newborns, and elderly adults [1, 2]. It is the 
most important viral pathogen causing acute lower respiratory tract infections (ALRI) in infants 
younger than 5 years old and it is estimated to have resulted in ~3.4 million hospitalizations and 
~200,000 deaths worldwide in 2005 [3]. RSV is transmitted by direct and indirect contact of 
nasal or oral secretions from an infected individual and primarily targets the lower airway 
respiratory epithelium (bronchioles) [4]. Clinical signs in infants and in children develop four to 
six days after infection with RSV, and usually subside after one to two weeks [5]. These signs 
vary with severity of disease and range from mild flu-like symptoms (coughing, sneezing, fever, 
and loss of appetite) in 25% to 40% of first-time exposed infants to severe bronchiolitis with or 
without pneumonia (rapid breathing, difficulty breathing, and wheezing) necessitating 
hospitalization in 0.5% to 2% of infants[6]. In very young infants, irritability, decreased activity, 
and apnea may be the only symptoms of infection. These clinical symptoms have been attributed 
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to both the immune response to RSV, as well as the direct damage to RSV-infected bronchiolar 
epithelium [7, 8]. 
            Current treatment of RSV infection is limited to supportive care. There exists an inhaled 
nucleoside analog (Ribavirin) that is approved for therapeutic use but which has limited 
treatment efficacy, as well as a monoclonal antibody (Synagis®, palivizumab), but whose use is 
limited to prophylactic application in high risk infants [9]. Two major hurdles in the 
development of preventative and therapeutic regimens are (i) the safety considerations following 
vaccination in young infants exemplified by the disastrous initial formalin-inactivated vaccine 
clinical trials where vaccination potentiated the disease rather than being protective and (ii) the 
lack of an available, clinically relevant model of RSV infection [10]. 
            Animal models developed to study RSV infection include mice, cotton rats, ferrets, non-
human primates, cattle, and lambs [9]. Lambs have several biological features that closely mimic 
RSV infection in human infants such as: similarities to human infants in lung development, lung 
structure and airway branching, cellular composition and immune responses, survival after late-
preterm birth, susceptibility to various strains of RSV including human strains (Long, A2, and 
Memphis Strain 37), similar histologic lesions and lung size to human infants, and the ability to 
obtain lambs lacking maternal antibodies [11–15]. Despite these advantages and the many 
previous and on-going studies of RSV infection in lambs, the progressive development of 
clinical signs, lung pathology and inflammatory/immune responses over time after inoculation 
with a human strain of RSV have not been fully characterized. Thus, the aim of this study was to 
gain further insight and understanding of the effects of RSV infection in the neonatal lamb model 
throughout infection (days 1, 3, 4, 6 and 8 after inoculation) with the human RSV Memphis 
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Strain 37. This kinetic information is needed in order to more fully characterize and utilize the 
lamb model for therapeutic and vaccine studies. 
Material and Methods 
Experimental Design 
            Colostrum-deprived neonatal lambs (2–7 days of age) received daily antibiotics 
(Ceftiofur, Pfizer, New York, NY; 1–2 mg/kg, intramuscular) to prevent secondary bacterial 
infections. They were randomly assigned to five M37 hRSV-infected groups, of 3 lambs (n = 3). 
Each lamb received three 2-mL installments of 1.27 x 107 FFU/mL in DMEM over a 23-minute 
period using a PARI LC Sprint™ nebulizer (PARI Respiratory Equipment, Inc., Lancaster, PA, 
USA) at 4L/min at 16 PSI (Philips Respironics Air Compressor, Andover, MA, USA) attached to 
a conical mask fitted with a round rubber diaphragm with a pre-cut center hole through which the 
nose and mouth of the lamb was inserted (MidWest Veterinary Supply, Inc., Burnsville, MN). 
Following infection, lambs were euthanized by sodium pentobarbital overdose and necropsied at 
different days post viral infection (p.i.): days 1, 3, 4, 6, and 8 p.i. After euthanasia the thorax was 
opened, lungs were removed, and RSV gross lesions (not including bacterial pneumonia lesions) 
were scored and photographed ex vivo. Tissue samples were collected from each lung lobe of all 
animals in the same manner, with uniform sampling of each lobe, and avoiding areas of bacterial 
pneumonia. Before lung dissection, bronchoalveolar lavage fluid (BALF) was collected from the 
right caudal lung lobe for infectious Focus-Forming Unit (FFU) assay and RT-qPCR for M37 
hRSV total nucleoprotein RNA and accessory lobe, for cytology (total and differential cell 
counts), as described below. Three samples from each lobe were snap frozen in liquid nitrogen 
for reverse transcription quantitative polymerase chain reaction (RT-qPCR), and two samples 
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from each lobe were placed in tissue cassettes and put in 10% neutral-buffered formalin for 
histological and immunohistochemical analyses.  
            Due to limitations in housing and number of lambs that can be handled in one study, the 
day 6 assessments were derived from an additional group of 3 lambs that was infected shortly 
after the necropsy of the other groups. The procedures, viral stock used and animal handling 
were identical to the viral kinetic (VK) study. The only difference was that the day 6 animals 
were slightly younger and lighter than the VK study animals as these came from another supplier 
(mean bodyweights of 3.4 ± 0.17 vs 6.3 ± 0.24 for the VK study on day 0; mean± se). In 
accordance to the 3R-principles, control lambs were not included in this study as previous work 
in our lab showed that non-infected lambs entirely lacked evidence of clinical illness, lung 
pathology, or immune and inflammatory changes that are consistent with M37 hRSV infection 
[1, 16-20].  Animal use and experimental procedures were approved by Iowa State University’s 
Animal Care and Use Committee (IACUC). 
Virus 
            Memphis 37 (M37) RSV is a wild type RSV-A, first isolated from a 4 month old infant 
[21] and used in human clinical studies [22–24]. The Memphis 37 RSV strain used in this study 
was passaged 6 times on Vero cells then twice on HEp-2 cells. Sucrose was added to 20% and 
the virus stock was frozen at −80°C and titered for infectivity on HEp-2 cells as we have 
characterized previously in this model [20]. 
Monitoring of Clinical Signs 
            Lambs were monitored daily for body weights, rectal temperatures, heart rate and percent 
blood oxygenation measurements (PalmSAT® 2500A VET pulse oximeter, Nonin Medical Inc., 
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Plymouth, MN, USA), and manual heart and respiratory rates (by auscultation). Increased 
expiratory effort (forced expiration) was scored daily as were animal “wheeze” scores (Table 1). 
Table 1. Scoring criteria for lung function by auscultation 
Score 
Expiratory efforts 
 
Wheezing 
(High-pitched whistling sound made while 
breathing) 
0 No expiratory effort No wheeze 
1 
Earliest detection of 
increased expiratory effort 
Earliest detectable wheeze by auscultation 
2 
Moderate expiratory effort 
(>1 sec) observed with some 
abdominal effort 
Audible wheeze in all lung fields by 
auscultation 
3 
Expiratory effort (>3 sec) 
with hard abdominal effort 
Wheeze audible without stethoscope 
 
Collection of Nasal Wash Fluid (NWF) 
            Just before euthanasia the nasal cavity of each lamb was washed with double-modified 
Iscove’s medium (DMIM) containing 42.5% Iscove's modified Dulbecco's medium, 7.5% 
glycerol, 1% heat-inactivated FBS, 49% Dulbecco’s Modified Eagle medium (DMEM), and 5 
μg/mL kanamycin sulfate. Using a 6-mL syringe fitted with a mucosal atomization device 
(MAD) conical foam end-piece (Intranasal Mucosal Atomization Device, Wolfe Tory Medical, 
Inc., Salt Lake City, UT, USA) a single 5 mL aliquot of DMIM was instilled into the right nare, 
and then (while still preserving a good seal between the nare and the MAD-device conical end-
piece), any out-coming fluid was extracted fairly quickly, in one motion, back into the delivery 
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syringe to collect (1.3–2.5 mL) NWF; which was dispensed into a 15 mL conical tube and placed 
on ice. 
Collection of Bronchoalveolar Lavage Fluid (BALF) 
            Following euthanasia the lungs of each lamb were removed and each left and right lung 
was separated and weighed. The excised right caudal lung lobe was instilled with 5 mL of cold 
DMIM (42.5% Iscove's modified Dulbecco's medium, 7.5% glycerol, 1% heat-inactivated FBS, 
49% DMEM, and 5 μg/ml kanamycin sulfate) after which 1 mL of the resulting BAL fluid was 
placed on ice and spun down for 5 minutes in a centrifuge at 3,000 x g to pellet large debris. 
Approximately 800–850 μL of each supernatant was collected and then spun through 850 μL-
capacity 0.45 μm Costar SPIN-X filter (microcentrifuge 15,600 x g) for 5 minutes before being 
used in the standard infectious focus forming unit assay (FFU). 
Gross Lesions Evaluation and Scoring 
            Following euthanasia, the thorax was opened and the heart and esophagus were removed 
from the lungs. The percentage parenchymal involvement of gross RSV lesions was scored for 
each individual lung lobe, and if present, the area and amount of lung lobes affected by bacterial 
pneumonia was also recorded. The percentage of a specific lobe tissue that was affected by RSV 
in relation to the overall lobe tissue being scored was estimated based on a score as done 
previously [1]. Mean percentage averages per lobe were calculated for each day of necropsy. 
Histologic Evaluation and Scoring 
            A histologic score was given by determining percent involvement followed by 
conversion to an additional integer-based consolidation scale used by our laboratory previously 
[1] wherein: 0% consolidation = 0; 1%-9% consolidation = 1; 10%-39% consolidation = 2; 40%-
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69% consolidation = 3; 70%-100% consolidation = 4. In total, multiple fields from 4 slides per 
animal were scored for the lesions. Each slide contained 2 different sections from the same lobe. 
Histologic score for each animal was the mean of all 4 slides and group averages were calculated 
for the alveolar consolidation score. In addition to the consolidation score, 
bronchitis/bronchiolitis, neutrophil infiltration, peribronchiolar and perivascular infiltration of 
lymphocytes, syncytial cell formation, and epithelial alterations were also scored according to 
criteria indicated in Table 2.  
Table 2. Histologic lung lesion scoring criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Score Bronchitis Bronchiolitis 
Syncytial 
cells 
Epithelial 
necrosis 
(bronchi or 
bronchioles) 
Epithelial 
hyperplasia 
(bronchi, 
bronchioles) 
Neutrophil (in 
bronchi, 
bronchioles 
or alveoli) 
0 
no remarkable 
lesions 
no remarkable 
lesions 
none none none none 
1 
minimal detectable 
lymphoplasmacytic 
infiltrates in lamina 
propria and 
adventitia 
minimal 
detectable 
lesions 
(epithelial 
degeneration) 
in one or a few 
bronchioles 
per 20x field 
one 
distinct 
syncytial 
cell 
minimally 
detectable in 
one or a few 
per 20x field 
minimally 
detectable in 
one or a few 
airways per 
20x field 
minimally 
detectable 
2 
segmental to 
circumferential 
infiltrates 
epithelial 
degeneration 
involving less 
than 10% of 
the airway 
lumen; 
minimal 
neutrophils, 
cell debris; 
adventitial 
lymphocytes 
in multiple 
bronchioles 
up to 
three in 
three 20x 
fields 
10% in 
multiple 
airways per 
20x field 
10% of airway 
per 20x field 
10 or less 
neutrophils in 
one or a few 
airways/alveoli 
3 dense infiltrates 
epithelial 
degeneration 
involving >10-
50% of the 
airway lumen 
with cell 
debris, 
neutrophils; 
adventitial 
lymphocytes; 
multiple 
bronchioles 
more than 
three in 
three 20x 
fields 
10-50% in 
multiple 
airways per 
20x field 
10-50% in 
multiple 
airways per 
20x field 
10 or more 
neutrophils in 
several 
airways/alveoli 
4 
infiltrates with 
nodular aggregates 
circumferential 
bronchiolitis 
with dense 
adventitial 
lymphocytes; 
multiple 
bronchioles 
Numerous 
in three 
20x fields 
circumferential 
in multiple 
airways 
circumferential 
10 or more 
involving 
many/most 
airways/alveoli 
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Table 2. (continued) 
Immunohistochemistry for Viral Antigen Detection 
Immunohistochemistry for the detection of RSV antigen was performed on 5 μm-thick 
formalin-fixed paraffin-embedded (FFPE) lamb lung tissue sections taken from the right and left 
cranial, left middle, and left caudal lung lobes of each animal in accordance with methods 
published previously [17, 25], but with the following variations: instead of Pronase E antigen 
retrieval, heated buffer antigen retrieval was performed in TRIS-EDTA-0.05% Tween 20, pH 9.0 
in a pressure cooking device (Decloaking Chamber
™
 Plus, Biocare Medical, Concord, CA) using 
the factory default 40-minute program (125°C reached in 18 minutes and cooling to 80°C in 
another 22 minutes). Primary polyclonal goat anti-RSV (all antigens) antibody (EMD Millipore 
Corporation, Billerica, MA, USA) was applied for 90 minutes at room temperature diluted 1:500 
in TBS-tween containing 10% NSS and 3% BSA. After rinsing with TBS-tween, biotinylated 
Score 
Bi nodules (these 
are 
peribronchiolar 
lymphocytic 
infiltrates) 
Vessel nodules 
(lymphocytic 
infiltrates 
around blood 
vessels) 
Eosinophilic 
infiltrates in 
bronchi or 
bronchioles, 
alveoli 
Eosinophilic 
infiltrates in 
vessels 
Eosinophils in vessel 
lumens 
0 none none none  none none 
1 
earliest detectable 
lymphocytic 
infiltrates in the 
adventitia 
earliest detectable 
lymphocytic 
infiltrates in the 
adventitia 
minimally 
detectable 
minimally 
detectable 
minimally detectable 
2 
segmental to 
circumferential 
infiltrates 
segmental to 
circumferential 
infiltrates 
up to five 
eosinophils in one 
to several 
airways/alveoli 
per 20x field 
up to five 
eosinophils 
associated with a 
vessel 
up to five in one or a 
few vessels 
3 
circumferential 
infiltrates that 
expand more than 
three cells wide 
circumferential 
infiltrates that 
expand more than 
three cells wide 
over five in over 
five airways per 
20x field 
> five in over five 
vessels per 20x 
field 
> five in over five 
vessels 
4 
circumferential 
infiltrates that form 
nodules 
circumferential 
infiltrates with 
nodules 
dense 
accumulations of 
eosinophils 
dense 
accumulations of 
eosinophils 
dense accumulations 
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rabbit anti-goat secondary antibody (Kirkegaard-Perry Labs, Gaithersburg, MD, USA) diluted 
1:300 in TBS-tween containing 10% NSS and 3% BSA was applied for 45 minutes, after which 
slides were rinsed with TBS-tween, treated with 3% H2O2 in TBS-tween for 25 minutes, rinsed 
and then incubated with streptavidin-conjugated HRP (Invitrogen) diluted 1:200 in TBS-tween 
for 30 minutes. Development of the color was performed in custom 12-slide plastic containers 
(Antibody Amplifier
™
 containers, ProHisto, LLC, Columbia, SC, USA) by applying Nova Red 
(Vector Laboratories, Inc.) for about 90 seconds followed by copious rinses with ddH2O, 
counterstaining with Harris’ hematoxylin (for 2 minutes), bluing with alkaline Scott’s water (for 
1 minute), dehydration and coverslipping with Permount mounting medium (Sigma, St. Louis, 
MO, USA). 20 unique 10X fields on each slide (containing two lung sections each) were 
assessed for RSV antigen staining by counting positively-stained cells within bronchioles and 
alveoli. The mean number of stained bronchi/bronchioles and alveoli per field were counted for 
each day of necropsy. 
Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) Assessment of 
RSV and Chemokine Gene mRNA Expression Levels in Lamb Lung 
             For each animal, tissue samples from right and left cranial, left middle and left caudal 
lung lobes (0.3–0.4 g of each lobe) were homogenized for total RNA isolation in TRIzol 
(Invitrogen) and previously described methods [1]. RNA was assessed for quantity and purity by 
spectrometry (Beckmann DU® 640B, Beckmann Coulter Inc., Brea, CA, USA) and all 
OD260nm/280nm values measured between 1.96 and 2.12. Agilent Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA, USA) analysis of RNA prior to DNase treatment consistently 
yielded RIN values ≥8.0 for all lamb lung RNA samples isolated this way [16]. Reverse 
transcription quantitative polymerase chain reaction (RT-qPCR) was performed using One-Step 
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Fast qRT-PCR Kit master mix (Quanta, BioScience, Gaithersburg, MD, USA) in a GeneAmp 
5700 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA) and PREXCEL-Q 
for all set up calculations [26, 27]. Primer and probe sequences for all targets were designed with 
ABI Primer Express 2.0, and have been used previously [1, 17, 28]. Primers and hydrolysis 
probe for targeting M37 hRSV NP RNA were designed using ABI Primer Express version 2.0 
based on RSV accession number M74568. Thermocycling conditions were 5 minutes at 50°C; 30 
seconds at 95°C; and 45 cycles of 3 seconds at 95°C and 30 seconds at 60°C. Samples and 
standards were assessed in duplicate, and each target gene quantification cycle (Cq) value was 
converted to a relative quantity (Qr) based on each target’s standard curve using: Qr = EAMP(b-
Cq), wherein “b” and “EAMP” are the y-intercept and exponential PCR amplification value, 
respectively. EAMP values were obtained from the slope (m) of each target standard curve by: 
EAMP = 10(-1/m), and all Qr values interpolated from standard curves were normalized to total 
lung RNA per RT-qPCR (0.784 ng RNA/μL for all reactions). No-RT control (NRC) reactions 
gave either no signal or generated Cq values greater than 13 cycles later than those in the 
corresponding RT-qPCR target reactions. 
Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) for RSV in 
Nasal Wash Fluid and Bronchoalveolar Lavage Fluid 
             Viral RNA was quantified by reverse transcription quantitative polymerase chain 
reaction (RT-qPCR) in NWF and BALF obtained from each animal at necropsy. NWF was 
obtained from the right nasal cavity and BALF from the right caudal lung lobe of each animal 
(see section on NWF and BALF collection). Briefly, 100 μL of each collected fluid sample was 
pipetted directly into 1 mL of TRIzol (Invitrogen/Life Technologies, Carlsbad, CA, USA) on ice, 
inverted to mix, and then transferred to -80°C for storage until RNA isolation and subsequent 
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RT-qPCR. Upon thawing, each 1.1 mL sample was vortexed for 10 seconds and allowed to sit at 
room temperature for 10 minutes. RNA isolation from NWF and BALF samples continued as per 
manufacturer’s instructions. The resulting (non-visible) RNA pellets, were each dissolved in 100 
μL of nuclease-free water (Invitrogen/Life Technologies), vortexed thoroughly, microfuged 
briefly, warmed to 60°C for 3 minutes, vortexed for 5 seconds, microfuged briefly, then 80 μL of 
each was diluted 1:10 with a combination of 10 μL RNaseOUT™ (to 0.5 Units/ μL), and 710 μL 
nuclease-free water, then stored at 4°C prior to RT-qPCR. RT-qPCR for RSV was then carried 
out as described above in the section: “Reverse transcription quantitative polymerase chain 
reaction (RT-qPCR) assessment of RSV and chemokine gene mRNA expression levels in lamb 
lung”. 
Focus-Forming Unit (FFU) Assay 
             Viral titers in both nasal wash fluid (NWF) and bronchoalveolar lavage fluid (BALF) 
from the right lung caudal lobe were determined using an infectious focus assay (FFU). In brief, 
200 μL of serially-diluted NWF or BALF samples were applied to HEp-2 cells grown to 70% 
confluence in 12-well culture plates (Fisher Scientific, Hanover Park, IL) in DMEM media 
(Mediatech, Inc., Manassas, VA) supplemented to 10% with heat-inactivated fetal bovine serum 
(FBS) (Atlanta Biologicals, Atlanta, GA) and 50 μg/mL kanamycin sulfate (Invitrogen/Life 
Technologies). Each sample was analyzed undiluted and at four additional serial-dilutions of 
1:10, 1:100, 1:1,000 and 1:10,000 in duplicate. Following a 48-hour incubation at 37°C, 5% 
CO2, the cells were fixed with cold 60% acetone/40% methanol solution for 1 minute. Overnight 
primary polyclonal goat anti-RSV (all antigens) antibody (EMD Millipore Corporation, Billerica, 
MA, USA) incubation was followed by washing and secondary antibody (Alexa Fluor® 488 
F(ab’)2 fragment of rabbit anti-goat IgG (H+L), Molecular Probes/Life Technologies) incubation 
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for 30 minutes. Plates were rinsed and inspected for the presence of fluorescing foci of infection 
using the FITC/GFP filter on an inverted fluorescence microscope (Olympus CKX41, Center 
Valley, PA). Five or more fluorescing cells were counted as single focal events. An average of 
40 counts in a 1:10-diluted (duplicate) sample indicated an original NWF or BALF sample 
“titer” of 2,000 [40 counts x dilution of 10 x 1,000 μL/mL]/200 μL assessed = 2,000 infectious 
focus-forming units/mL (FFU/mL). 
Results 
Clinical Findings 
            Following RSV-infection, there were no differences in weight gain, body temperature, 
heart rate, and percent blood oxygen saturation when compared to control lambs from previous 
studies in which the procedures, facilities, animal handling, and source and age of lambs were 
similar [1, 16–20]. Despite a small drop in mean blood oxygen saturation levels on day 6 (92.4% 
± 2%; mean ± SD) when respiratory distress was present in most lambs, these remained above 
the 90% limit. Respiratory rates (not shown) were variable and non-predictable for each day of 
the study and were likely confounded by the heavy sampling schedule and the resultant stress 
level of the newborn lambs. Increased expiratory efforts and wheezing were the only noteworthy 
clinical features observed in RSV-infected lambs in this study. Following inoculation with M37 
hRSV, expiratory efforts became apparent on day 3 in 4 out of 12 lambs (33%). On day 5 this 
proportion increased to 4 out of 6 lambs (66%) and on day 6 to 5 out of 6 lambs (83%). By day 7 
all lambs (100%) had increased expiratory efforts, but on day 8 this proportion dropped to 2 
lambs out of 3 (66%). The severity of expiratory efforts increased from day 3 to day 7 as shown 
by the mean expiratory effort score (Fig 1A). Similarly, wheezing was apparent on day 3 
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although only in 1 out of 12 lambs (8.3%). The proportion of lambs that developed wheeze 
gradually increased to reach a peak on day 5 (83.3%) and decreased on day 8 (33%). The mean 
wheeze score followed a similar time profile (Fig 1B). 
0 2 4 6 8
0 .5
1 .0
1 .5
2 .0
2 .5
E x p ira to ry  e f fo r ts
D a y s  p o s t-in fe c tio n
M
e
a
n
 e
x
p
ir
a
to
r
y
 e
ff
o
r
ts
 (

s
e
)
R S V  M 3 7
A .
0 2 4 6 8
0 .5
1 .0
1 .5
2 .0
W h e e z e
D a y s  p o s t-in fe c tio n
M
e
a
n
 w
h
e
e
z
e
 s
c
o
r
e
 (

s
e
)
R S V  M 3 7
B .
 
Figure 1. Respiratory distress score of lambs inoculated with human respiratory syncytial virus 
(hRSV) strain Memphis 37 (M37). Respiratory distress score was assessed daily for each lamb 
by auscultation or visual observation, and was categorized by expiratory effort (A) and wheezing 
(B). Result are shown as mean ± standard error. 
 
Gross and Microscopic Lung Lesions 
            Following necropsy, gross examination of the lungs determined the percent of each lobe 
that was covered with typical RSV-induced lesions. In some cases, areas of lung with lesions 
suggestive of bacterial pneumonia were also present along with RSV-induced lesions, and lung 
lobes with lesions suggestive of bacterial pneumonia were recorded, but not scored as RSV 
lesions. RSV lesions were bilateral, evenly-distributed and characterized by multifocal to locally 
extensive dark plum-red, well-demarcated foci of pulmonary consolidation which varied from 
mild to severe (Fig 2A); consistent with RSV infection in lambs as reported previously [1, 17, 
29]. In contrast to RSV lesions, lung lobes affected by bacterial pneumonias were mild, 
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unilateral, and cranial ventral (right and middle lung lobes being mostly affected), and were 
characterized by multifocal, locally extensive, firm, red-brown areas. Following RSV-infection, 
gross RSV viral lesions were already detectable on day 1, and further increased by day 3, to 
reach maximal levels by day 6 of around 40% and decreased thereafter (Fig 2B). For the lambs 
used in this study, only the last group of lambs (10 and 12) necropsied at day 8, had gross lesions 
of bacterial pneumonia affecting the right middle lung lobe. For day 6 lambs, lamb 14 had 
bacterial pneumonia affecting the right cranial and middle lung lobes. Again, these lung regions 
bearing non-RSV-induced lesions were not sampled for attaining experimental endpoints. 
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Figure 2. Scoring of gross lesions caused by M37 hRSV in lambs.Viral gross lesions caused by 
M37 hRSV infection in neonatal lambs. (A) Picture of a lung on day 6 post-infection. Dark 
plum-red, well-demarcated foci of pulmonary consolidation are indicated by arrowheads. (B) 
Percentage parenchymal involvement was estimated for each lung lobe and mean percentage 
averages per lobe were calculated for each day of necropsy (± standard error). Legend: Rt Cr = 
Figure 2. (continued) Right cranial lobe; Rt Mid = Right Middle lobe; Rt Cd = Right Caudal 
lobe; Acc = Accessory lobe; Lt Cr = Left Cranial lobe; Lt Mid = Left Middle lobe; Lt Cd = Left 
Caudal lobe.  
 
             Microscopically, lungs of infected lambs had multifocal to coalescent foci of an 
inflammatory infiltrate that partially filled the lumen of bronchi/bronchioles, alveolar spaces, and 
alveolar septa. The airway lumen was also partially occluded by seroproteinaceous fluid and cell 
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debris intermixed with mucin. These lesions increased progressively with time and were similar 
to those described previously with M37 hRSV and with hRSV A2 strains [1, 17, 18, 25]. On day 
1 p.i., small numbers of neutrophils were present within the lumen of bronchioles and occasional 
bronchi. On day 3, microscopic lung lesions were characterized by mild to moderate infiltrates of 
neutrophils in bronchiolar lumens with small amounts of seroproteinaceous fluid and mucin. A 
mild but detectable infiltration of lymphocytes in the tunica adventitia of bronchioles and nearby 
blood vessels was also present. There was degeneration (cells with rounded cell borders and 
basophilic/pyknotic nuclei) of epithelial cells in bronchioles (Fig 3A). The intensity of the 
lesions were further increased on day 4 and characterized by the neutrophil infiltration with 
sloughed, necrotic epithelial cells, seroproteineous fluid and small amounts of mucin in 
bronchioles and bronchi along with occasional macrophages and the formation of occasional 
syncytial cells in bronchio-alveolar spaces. The alveolar septa were mildly to moderately 
thickened by hyperplasia of type II pneumocytes and the bronchioles were surrounded by 
moderate to mild numbers of lymphocytes and plasma cells; a few lymphocytes were present 
within the alveolar septa. By day 6, all observed lesions present on day 4 peaked, with the 
notable exception of lymphocytic infiltration in the peribronchiolar region and blood vessels. 
Neutrophils were prominent on day 6 p.i. but reduced/absent on day 8 p.i. which is consistent 
with our previous studies in the lamb model [17, 28]. Peribronchiolar and perivascular 
lymphocyte infiltration was increased on day 8 while all other parameters were reduced (Fig 3B). 
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Figure 3. Microscopic lung lesions severity score in M37 hRSV infected neonatal lambs. (A) 
Histopathologic lesions included bronchiolitis with degenerate/necrotic individual epithelial cells 
(thin arrow), occasional syncytial cells (long arrow), accumulation of degenerate neutrophils 
(short arrow), and occasional macrophages. H&E Bar = 50 µm. (B) A histologic score was given 
by determining percent consolidation followed by conversion to an integer-based consolidation 
scale used by our laboratory previously [1]: 0% consolidation = 0; 1%-9% consolidation = 1; 
10%-39% consolidation = 2; 40%-69% consolidation = 3; 70%-100% consolidation = 4. Group 
averages were calculated for alveolar and bronchiolar consolidation scores. In addition to the 
consolidation score, bronchitis, bronchiolitis, neutrophil infiltration, peribronchiolar and 
perivascular infiltration of lymphocytes, syncytial cell formation, and epithelial alterations were 
also scored. Results are indicated as mean ± standard error for each scored parameter.  
 
 
40 
 
 
Viral Titers, Viral RNA Levels and Viral Antigen Expression 
             Levels of M37 hRSV total nucleoprotein RNA in lung tissue, BALF, and NWF were 
measured by RT-qPCR, while cultivatable virus was quantified by infectious focus (FFU) assay 
in NWF and BALF collected on each day of necropsy. Viral titers and viral RNA in BALF and 
lung tissue increased progressively from day 1 to day 3 and were sustained or increased slightly 
until day 6. On day 8, viral titers and RNA decreased substantially as observed for all other 
virology endpoints (viral antigen expression, gross lung lesions, and microscopic lesions). In 
contrast, viral titers and viral RNA levels in NWF were more variable when comparing them to 
levels in BALF and lung tissue. Viral titers in NWF were highest at day 3 (1.7 log10 FFU/mL), 
whereas this was the case on day 6 (2.9 log10 RNA copies/mL) for viral RNA. Overall, 
intranasal viral replication was substantially lower than viral replication in the lung (Table 3) and 
may be due to the administration of virus by nebulization which may bypass the nose to some 
extent or be indicative of a lower permissiveness of lamb nasal epithelial cells for RSV 
replication. 
            With immunohistochemistry, RSV antigen was present in areas with microscopic lesions. 
Within these areas, RSV antigen was present in the entire cytoplasm of epithelial cells lining 
bronchi and bronchioles, alveoli, and the cytoplasm of occasional macrophages (Fig 4A). On day 
1 p.i. no viral antigen expression was detected in the lungs of infected lambs and was only 
apparent on day 3 predominantly in the epithelial cells of bronchi and bronchioles when 
compared to the alveoli. There was an increasing progression of viral antigen expression in both 
bronchi/bronchioles and alveoli, which reached a peak on day 6 with a marked shift in viral 
antigen expression occurring in the alveoli. Degenerate and necrotic epithelial cells within 
lumens of bronchioles also contained viral antigen at days 3, 4, and 6. On day 8, viral antigen 
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expression in lung tissue had decreased substantially (Fig 4B) consistent with a decline in RSV 
titers in lung (Table 3). 
Table 3. Quantification of RSV replication via RT-qPCR and infectious focus assay in 
lambs inoculated with M37 hRSV 
Parameter Day 1 Day 3 Day 4 Day 6 Day 8 
Viral load 
(Nasal 
Washes)* 
 
Viral culture 
(Log10 FFU/mL ± se) 
BDL (0.7) 1.7 ± 0.4 0.6 ± 0.1 0.99 ± 0.3 0.8 ± 0.1 
RT-qPCR 
(Log10 M37 RNA 
copies/mL ± se) 
1.44 ± 1.1 1.68 ± 1.4 0.42 ± 0.1 2.89 ± 0.34 1.46 ± 1.2 
Viral load 
(BALF)* 
 
Viral culture 
(Log10 FFU/mL ± se) 
2.53 ± 0.09 4.60 ± 0.32 3.94 ± 0.25 4.83 ± 0.04 1.02 ± 0.32 
RT-qPCR 
(Log10 M37 RNA 
copies/mL ± se) 
3.80 ± 0.03 6.22 ± 0.08 6.20 ± 0.16 7.15 ± 0.2 4.70 ± 0.38 
Viral 
transcripts 
(Lung 
tissue) 
RT-qPCR 
(Log10 M37 RNA 
copies/mg lung tissue ± se) 
4.81 ± 0.15 6.51 ± 0.08 6.67 ± 0.25 7.63 ± 0.07 5.24 ± 0.26 
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Figure. 4. Immunohistochemistry and scoring of RSV antigen expression in lambs inoculated 
with M37 hRSV. Immunohistochemistry was used to detect viral antigen using an all-antigens 
polyclonal antibody for RSV. RSV immunoreactivity is shown within epithelial cells lining the 
bronchioles (brown cells). The mean number of virally-infected bronchi/bronchioles and alveoli 
per field was counted for each day of necropsy. Bar = 50 µm. 
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Chemokine and Cytokine Expression in Lung Tissue 
            Lung cytokine mRNA expression levels were quantified by RT-qPCR and demonstrated 
varying patterns of expression in M37 hRSV-inoculated lambs throughout infection. While IL-10 
expression levels were highest on day 3 post-infection other chemokines and cytokines had 
maximal expression at later timepoints (e.g. TGF-β on day 4; IL-8, RANTES and MCP-1α on 
day 6 and IFN-γ on day 8) (Fig 5). Similarly, previous results from our laboratory have shown 
that MCP-1α, MIP-1α, RANTES, IFN-γ, and IL-8 were increased upon RSV-infection in 
neonatal lambs on day 6 [1], whereas the anti-inflammatory mediator, IL-10, was down regulated 
at day 6 post-infection, but increased on day 3 post-infection [28]. 
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Figure 5. Lung chemokine and cytokine mRNA expression by RT-qPCR in lambs inoculated 
with M37 hRSV.  
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Figure 5. (continued) Lung tissue obtained from each animal was evaluated for the following 
mRNA targets:  surfactant protein A (SP-A), surfactant protein D (SP-D), interleukin 8 (IL-8), 
interleukin: (IL-10), macrophage inflammatory protein 1 alpha (MIP-1α), monocyte chemotactic 
protein 1 alpha (MCP-1α), tumor necrosis factor alpha (TNF-α), transforming growth factor beta 
(TGF-β), interferon beta (IFN-β), interferon gamma (IFN-γ), programmed cell death 1 ligand 1 
(PD-L1), and regulated on activation normal T-cell expressed and secreted (RANTES). Mean 
relative mRNA expression was calculated for each target with respect to each day of necropsy. 
Relative mRNA expression means:  relative to the total amount of RNA loaded per reaction 
(which is kept constant) and relative to the values established by the standard curves for each 
target.  
 
Discussion 
This study aimed to determine the time course of M37 hRSV replication in neonatal 
lambs and the corresponding pathophysiology i.e. clinical signs (wheezing, respiratory distress), 
airway inflammation, and lung histopathology. Such a time course is difficult to assess in infants 
since the diagnosis is often only done at the time of or near peak viral titers. 
             Colostrum-deprived neonatal lambs are highly relevant for the study of RSV infection 
and may serve as a model of RSV infection in human infants due to the natural susceptibility of 
lambs to ovine, bovine and human strains of RSV as well as similarities in disease pathogenesis 
and anatomical, physiological and developmental similarities to that of human infants [13–15]. 
Experimentally, it has been shown that lambs and other ruminants can be infected with human or 
bovine RSV strains and that the infection induces lung lesions that resemble those observed in 
human RSV pathology such as bronchiolitis with epithelial cell necrosis, syncytial cell 
formation, hyperplasia of nearby epithelium and infiltrates of neutrophils with occasional 
macrophages [1, 11, 17, 29–33]. Moreover, RSV infected lambs develop mild to moderate 
clinical symptoms such as expiratory effort, fever, tachypnea, wheeze, malaise and listlessness 
[1, 11, 17, 29, 32] and formalin-inactivated RSV vaccination in lambs induces enhanced lesions 
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upon RSV infection [19] as observed in infants [34, 35]. To date, and to our knowledge, no study 
has yet specifically addressed the time course of viral replication, histopathology, airway 
inflammation, and associated clinical symptomatology (wheezing, respiratory distress) in 
neonatal lambs following infection by nebulized inhalation of the M37 hRSV strain. The purpose 
of this study, therefore, was to define the time course of Memphis 37 RSV replication in the 
lungs of neonatal lambs and the corresponding clinical features and pathophysiology. 
              Following RSV infection, this study demonstrates that there is robust viral replication as 
determined by titers and mRNA levels in the lungs, which peaked on day 3, were sustained until 
day 6 and decreased by day 8. Viral replication was present in the nasal cavity with maximal 
titers detected at days 3 (cultivatable virus) and 6 (mRNA) post inoculation, but this replication 
was less robust compared to lung, as viral titers were ~3 Log lower in the nasal wash fluid than 
in lung on day 3. Such differences in NWF and BALF titers may be related to the administration 
route which partly bypasses the nasal meatus and also because the sampling of nasal cavity 
(washes of a cavernous space) differs from solid lung tissue and BALF (taken from a bronchus 
directly at post mortem). The kinetics of RSV RNA expression levels in BALF and lung tissue 
displayed a similar profile. Viral antigen expression followed a similar time-profile as titers and 
mRNA levels, albeit with a delay, and was detected in intact and degenerate/necrotic bronchiolar 
epithelial cells and ciliated airway epithelial cells in bronchi; cell types that were shown to be 
permissive to RSV infection [36–41], as well as in the cytoplasm of occasional macrophages, 
consistent with the distribution of virus-infected cells in fatal cases of RSV-infection [33]. Viral 
antigen expression in bronchi/bronchioles and alveoli for each day post-inoculation followed the 
progression/severity of microscopic lung lesions, gross lung lesions, and respiratory distress. 
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              Microscopically, the bronchiolar epithelia had evidence of necrosis on days 3 and 4 and 
epithelial hyperplasia, which increased until day 6. The infected bronchiolar cells can, as a result, 
become degenerate and necrotic and contribute to the cell debris entering and partially occluding 
the airway lumen. In addition, the necrotic areas and the inflammatory mediators released in this 
process facilitate neutrophil infiltration and accumulation of seroproteinaceous fluid and mucin, 
all of which can further occlude the airway lumen. Lymphocytes were first observed by day 3 
and 4 and appeared to achieve peak levels by day 6 to 8. Immune cell infiltrates accumulated in 
the tunica adventitia of bronchi, bronchioles and small blood vessels, and slightly more 
macrophages were observed in the alveolar and bronchiolar lumens. On day 8 post-infection, 
airway lumens were observed to contain only occasional neutrophils and macrophages, while 
infiltrates of lymphocytes and plasma cells remained present in the adventitia, reflecting a 
change from neutrophilic to lymphocytic and plasmacytic inflammation. The role of 
lymphocytes in RSV clearance and convalescence has previously been evidenced in human and 
mouse studies [42–44] and the failure to develop an adaptive cytotoxic T lymphocyte response 
has been proposed to be related to the pathogenesis of RSV infection of the lower respiratory 
tract [45]. Conversely, neutrophils are the most abundant cell type recovered from the respiratory 
tract in infants-hospitalized for RSV disease [46–48] and it has been suggested that they can 
contribute significantly to epithelial cell damage and to disease severity [49, 50]. 
               In addition to inflammatory cell influx in the lungs, it has been shown that chemokines 
and cytokines, such as IL-8, RANTES, MIP-1α, IL-6 and IL-10 are increased in RSV-infected 
infants [49, 51–57] and likely to promote the intense inflammatory process present in the airways 
of these infants. For this reason, we sought to investigate the time course of chemokine 
expression in lung tissue from RSV-infected lambs. Expression of proinflammatory chemokines 
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and cytokines such as IL-8, IFN-γ, IFN-β, MCP-1α, MIP-1α and TNF-α or anti-inflammatory 
cytokines such as IL-10 was detected and was consistent with previously published data [1, 28]. 
Peak expression of IL-8 was present at day 6 post-infection and coincided with peak neutrophil 
influx in the lungs of RSV-infected lambs which indicates that the increased chemokine 
expression contributed to neutrophil infiltration into the site of intense RSV infection, in 
accordance with the role of IL-8 in neutrophil chemotaxis [7]. In contrast, IFN-γ expression, a 
cytokine mainly produced by NK cells and activated CD4+ and CD8+ T cells that promotes cell-
mediated immune responses to intracellular pathogens, was maximal at day 8 post-infection at a 
time when peak lymphocyte lung infiltration was noted. Taken together, this data suggests that 
RSV infection in neonatal lambs results in an initial innate inflammatory response, the peak of 
which coincides to that of peak disease, and is characterised by IL-8 secretion and neutrophil 
influx. During the transition from the initial inflammatory response, there is infiltration of 
lymphocytes and, as the disease resolves, the inflammatory response is characterised by IFN-γ 
secretion and continued lymphocyte influx. Interestingly, a suppressed lymphocyte function and 
increased plasma IL-8 levels were shown to be markers of severe disease in RSV bronchiolitis 
[58]. 
               The most interesting results, however, obtained in the current study were those related 
to the clinical parameters. Infants with RSV-disease typically develop clinical manifestations 
such as bronchiolitis and pneumonia symptoms of which include wheezing, crackles, rhonchi, 
tachypnea, nasal flaring, and intercostal muscle retractions [59, 60]. In our study, the neonatal 
lambs developed respiratory distress (forced expiration, abdominal breathing and wheeze) 
following RSV-infection consistent with previous reports [1, 18]. The progression of respiratory 
distress coincided with that of viral replication (titers, viral RNA and viral antigen expression), 
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lung gross viral lesions, and histopathological changes. The resultant partial occlusion of the 
small airways by sloughed epithelial cells, inflammatory cells, respiratory secretions and mucous 
plugs as observed microscopically may lead to air trapping, lung hyperexpansion and increased 
airway resistance causing respiratory distress [61]. The deterioration of lung function and clinical 
symptomatology thus appears to be a direct effect of viral replication and its induction of 
bronchiolar/lung pathology. In experimentally-infected adults, a similar close temporal 
association between onset, peak, and clearance of viral replication, and the onset, peak, and 
resolution of the disease, has been described as well. However, viral replication and disease are 
limited to the upper airways in this human model [22]. 
               This viral kinetic study of M37 hRSV in newborn lambs establishes a baseline of 
clinical features and pathology in a model where RSV infection and the consequences thereof 
resembles that of human infant RSV disease in the lower airways and may serve as a valuable 
tool to assess vaccine and antiviral drug safety and efficacy. 
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Abstract 
Rationale  
Rationale: Respiratory syncytial virus (RSV) is a common cause of acute lower 
respiratory disease in infants and young children worldwide. Currently, treatment is limited to 
symptomatic treatment, with no vaccines available. The use of neonatal lambs to model RSV 
infection in human infants may provide a valuable tool to assess safety and efficacy of vaccines 
and antiviral drugs. Nanobodies® are therapeutic proteins based on the smallest functional 
fragments of naturally occurring heavy chain antibodies. ALX-0171 is a trivalent Nanobody 
targeting the RSV fusion (F) protein. Its therapeutic potential was evaluated in newborn lambs 
infected with a human strain of RSV following daily ALX-0171 nebulization for 3 or 5 
consecutive days. 
Methods 
Colostrum-deprived newborn lambs were nebulized with RSV-M37 (~3.5 x 107 
FFU/lamb) on day 0, and were subsequently treated by daily nebulization after RSV-infection 
with either ALX-0171 or placebo. Two different treatment regimens were examined: day 1-5 or 
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day 3-5 post-infection. Lambs were monitored daily for general well-being and clinical 
parameters. Respiratory tissues and bronchoalveolar lavage (BAL) fluid were collected at day 6 
post-inoculation for the quantification of viral lesions, lung viral titers, viral antigen and lung 
histopathology. 
Results 
On day 3 post-infection, the general well-being of the placebo-treated lambs declined as 
was reflected by inactivity, lethargy, weakness, drooping of ears, and lack of appetite. A pilot 
study previously indicated that this is also the time of peak viral loads. Both viral RNA and 
cultivatable virus was consistently present in all lung lobes of these lambs on day 6. In addition, 
gross lung examination revealed extensive viral lesions involving ~40% of all lung lobes which 
were correlated to viral antigen expression in the bronchioli/alveoli. Histologically, the lesions 
were consistent with those described previously for lambs and infants after RSV infection. 
Following treatment with ALX-0171, treated lambs had a >10,000-fold decline in cultivatable 
virus, markedly reduced lung viral antigen expression, reduced lung viral lesions and reduced 
histological changes on day 6. ALX-0171 treatment exerted a positive effect on clinical 
parameters of the lambs and was well-tolerated. 
Conclusion  
Administration by inhalation of ALX-0171 was well-tolerated in RSV infected newborn 
lambs. Robust antiviral effects and positive effects on RSV-induced lung lesions and reduction in 
symptoms of illness were noted. These effects were still apparent when treatment start was 
delayed and coincided with peak viral loads (day 3 post-infection) and at a time point when signs 
of respiratory syncytial virus disease were apparent. The latter design is expected to have high 
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translational value for planned clinical trials. These results are indicative of the therapeutic 
potential of ALX-0171 in infants. 
Introduction 
Human respiratory syncytial virus (hRSV) is classified in the genus Orthopneumovirus of 
the newly created Pneumoviridae family within the order Mononegavirales, standing apart from 
the original Paramyxoviridae family member [1]. As such, it encodes two major surface 
glycoproteins termed G-protein and F-protein. These two glycoproteins play a crucial role in 
viral replication as they are responsible for viral binding to the target cell and virus-cell 
membrane fusion, respectively. In addition, RSV has a linear single stranded, non-segmented 
RNA molecule of negative-polarity of approximately 15kb.  
 As a respiratory virus, RSV infection may present as an upper respiratory tract infection 
(including rhinitis, otitis media and pharyngitis), or as a lower respiratory tract infection 
(including acute bronchiolitis or pneumonia) in vulnerable populations such as infants, elderly 
and immunocompromised adults [2]. This lower respiratory tract infection results in 
hospitalization in about 3% of RSV-infected infants less than 1 year old, and in about 0.5% of 
RSV-infected children aged between 1 and 2 years [3]. Each year, it is estimated that RSV 
causes at least 3.4 million lower respiratory tract infections requiring hospitalization and up to 
200,000 deaths worldwide in infants less than 5 years of age [4] and in approximately 177,000 
hospital admissions and 10,000–14,000 deaths per year in the United States in the elderly.  
Currently, there are no approved vaccines or effective therapeutic drugs specifically for 
RSV infection, with treatment being limited to supportive care. In severe RSV infections, the 
only approved antiviral treatment is the nucleoside analog Virazole (ribavirin), which is 
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delivered by inhalation. However, due to concerns for potential teratogenicity and minimal 
evidence of benefit it is not recommended for routine use in infants but may be considered for 
use in select patients with documented, potentially life-threatening RSV infection [5]. In the 
prevention of RSV infections, Palivizumab (Synagis®, MedImmune), a humanized monoclonal 
antibody (IgG) against the F-protein of RSV, has been approved for use in high risk infants; 
however, due to high costs associated with palivizumab prophylaxis, use is restricted to certain 
high-risk pediatric populations [6].  
There is thus a need to develop new therapeutic treatment options for RSV infection. 
Different animal models for RSV infection, including non-human primates, calves, lambs, mice, 
guinea pigs, ferrets, hamsters and cotton rats have been described [7, 8]. The cotton rat 
(Sigmodon hispidus) RSV infection model has been successfully used in the development of 
both RSV-IgIV (RespiGam®, MedImmune, Inc., Gaithersburg, MD, USA) and palivizumab and 
findings in the cotton rat for those agents translated well to the clinical setting [9, 10]. The cotton 
rat model also serves as the primary model for the determination of vaccine safety as they 
develop vaccine-enhanced pulmonary disease that reflects what is seen in humans and non-
human primates [11]. However, and although susceptible to RSV infection, cotton rats do not 
exhibit any clinical signs of upper and lower respiratory tract disease or any age-related 
susceptibility to hRSV in contrast to what is seen for human infants [8].  
Similarly to humans, lambs exhibit several key features of RSV vaccine enhanced disease 
[13]; anatomically, the respiratory tract of sheep and humans share many structural features, such 
as the size of the nasal cavity and airways [14] as well as lung development where 
alveolarization starts pre term [15]. When experimentally infected with either bovine (bRSV) or 
human (hRSV) strains of RSV, neonatal lambs develop mild clinical symptoms including fever, 
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tachypnea or increased expiratory effort (wheeze) and malaise, as well as mild to moderate gross 
and histologic lesions [12].  
ALX-0171 is a novel inhaled biotherapeutic in development for the treatment of RSV 
infections in infants [16]. Local pulmonary administration of ALX-0171 was considered optimal 
for this indication as it enables targeted delivery straight to the site of infection, with a 
potentially more rapid onset of action while using lower doses compared to systemic 
administration [17]. Preclinical evaluation of ALX-0171 using a face-mask, which is highly 
relevant for the intended clinical use, would thus require a larger animal species than rodents. In 
addition to the pathophysiological similarities of RSV disease with human infants, lambs also 
have advantages in terms of drug delivery by inhalation. Indeed, drug deposition in the lung is 
affected by the respiratory rates and breathing volumes, both parameters being dependent on 
body size [18], and lung anatomy which are similar to infants. Another important parameter that 
affects drug deposition is the breathing maneuver. Lambs are nasal breathers, although oral 
inhalation is possible when the nasal airways are obstructed, which is also the case for human 
infants [19]. For the reasons stated above, the neonatal lamb model was selected for the 
evaluation of ALX-0171 efficacy and safety in a neonatal setting.  
             Material and Methods 
Animals 
Male and female Suffolk, Polypay or Dorsett cross colostrum-deprived neonatal lambs 
(1-3 days of age) were obtained from local farms (Lester, Iowa, USA). Lambs were fed lamb 
milk replacer (Milk Products Inc., Chilton, WI, USA) that lacked supplemental iodide as of birth 
and were given Naxcel (Ceftiofur sodium, Pfizer) 1–2 mg/kg subcutaneously once daily to 
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reduce/prevent secondary bacterial infections. The animals had not been subjected to other 
experiments before the study. All efforts were made to minimize animal discomfort and limit the 
number of animals used. Study protocols were approved by the Institutional Animal Care and 
Use Committee (approval #12-12-7470-O) and were performed in accordance with the animal 
welfare bylaws of the Iowa State University which are in accordance with the Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC) regulations. The studies 
were also approved by the Institutional Biosafety Committee at Iowa State University. 
Compounds  
ALX-0171 is a trimeric Nanobody consisting of three RSV-targeting subunits linked by 
two glycine-serine linkers, and was produced using a Pichia pastoris X-33 expression system 
[16]. ALX-0171 formulation buffer which consists of NaCl as osmolality agent and phosphate as 
buffer component was used as a placebo. The formulation components and their concentration 
were selected based on their compatibility with pulmonary administration.  
Infection of Lambs 
PARI LC Sprint™ nebulizers (PARI Respiratory Equipment, Inc., Lancaster, PA, USA) 
were used to administer virus or cell-conditioned media (media from HEp-2 cells lacking hRSV) 
to each lamb. They were attached to a conical mask fitted with a round rubber diaphragm with a 
pre-cut center hole through which the nose and mouth of the lamb was inserted (MidWest 
Veterinary Supply, Inc., Burnsville, MN). Three 2-mL aliquots of virus-containing media or 
control media were administered to each animal over the course of 23 minutes at 4L/min at 16 
PSI (Philips Respironics Air Compressor, Andover, MA, USA) resulting in the total inhalation of 
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about 6 mL by each lamb. Identical viral inoculum doses were used for each lamb (hRSV M37 
strain at 1.27x 10
7
 FFU/mL in media with 20% w/v sucrose). 
Drug Administration 
An Aeroneb® Solo System (Aerogen Ltd, Galway, Ireland), consisting of the Aeroneb® 
Solo mesh nebulizer and the Aeroneb® Pro-X controller were used in accordance with the 
instruction manual as provided by the manufacturer. The estimated particle sizes obtained with 
these meshes were in the range of 3.27 ± 0.13 μm (MMAD). The assembly and operation of the 
Aeroneb® Solo System was done according to the nebulizer instruction manual. The nebulizer 
and the T-piece were inserted into the breathing circuit. Air was supplied to the system at an 
airflow speed of 2L/min using a compressed air canister that was attached directly to the 
nebulizer T-piece. 
Prior to dosing, the nebulizer reservoir was filled with either 4 mL (3 mg/kg target 
inhaled dose), 1.3 mL (1 mg/kg target inhaled dose) or 0.4 mL (0.3 mg/kg target inhaled dose) of 
ALX-0171 or ALX-0171 formulation buffer (placebo). A cone mask (Cat # 05305, A.M. 
Bickford, Inc, US) was attached to the nebulizer T-piece and was placed over the lamb’s nose, 
mandible and maxilla. The nebulizer was turned on at a constant nebulization mode and the cone 
mask was firmly held in place during the duration of the nebulization. Once the dose had been 
nebulized (i.e. when the nebulizer reservoir was empty) the face mask was removed and the 
nebulizer switched off. The lamb was then returned to its cage and general health (alertness, 
responsiveness, ability to stand and move) was monitored for 10 minutes. 
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Calculation of Inhaled Dose 
The total dose emitted by the nebulizer was determined per administration by weighing 
the nebulizer before and after the administration and deducing the nebulized volume. The 
nebulized volume of ALX-0171 was then multiplied by the concentration of ALX-0171 to 
determine the delivered dose. The inhaled dose per lamb (i.e. the dose reaching the tip of the 
snout) was estimated to be 11% of the delivered dose based on experiments in which a similar 
nebulizer setup as the one that was used in these studies was connected to a breathing simulator 
programmed for neonatal breathing. The inhaled fraction was defined as the fraction that was 
found back on the inhalation filter in relation to the total nebulized dose. The bodyweight 
adjusted inhaled doses were expressed as mg/kg and were calculated as the inhaled dose on each 
specific day divided by the measured bodyweight on the corresponding dosing day. 
Experimental Design 
Three independent studies were performed in which a total of fifty five lambs were 
randomly assigned based on weight and sex to three or four groups depending on the study 
(Table 1). In study 1, thirteen lambs were assigned to four groups (groups 1, 2, 3 and 4). Three 
lambs were in group 1 (RSV-infected placebo treated), four lambs were in group 2 (RSV 
infected 0.3 mg/kg ALX-0171 treated), three lambs were in group 3 (RSV infected 1 mg/kg 
ALX-0171 treated) and three lambs were in group 4 (RSV infected 3 mg/kg ALX-0171 treated). 
In study 2, ten lambs were assigned to three groups (groups 1, 2 and 3). Three lambs were in 
group 1 (RSV infected placebo treated), four lambs were in group 2 (RSV infected 0.3 mg/kg 
ALX-0171 treated) and three lambs were in group 3 (RSV infected 3 mg/kg ALX-0171 treated). 
In study 3, twenty two lambs were assigned to four groups (groups 1, 2, 3 and 4). Five lambs 
were in group 1 (uninfected placebo treated), six lambs were in group 2 (uninfected 0.3 mg/kg 
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ALX-0171 treated), five lambs were in group 3 (RSV infected placebo treated) and six lambs 
were in group 4 (RSV infected 0.3 mg/kg ALX-0171 treated) (see Table 1). 
Table 1. Summary of studies and groups 
S
Study 
  
Group 
number 
         Number of lambs 
        Infection Dose level 
Inhaled dose (mg/kg) 
Total  For analysis 
                 
            Target  
                Mean  
             achieved  
1
1 
     1    3         3            RSV Vehicle 0 0 
     2   4        4            RSV 
ALX-0171 
0.3 mg/kg 
0.3 0.3 
     3   3        3            RSV 
ALX-0171 
1 mg/kg 
1 0.8 
    4   3        2            RSV 
ALX-0171 
3 mg/kg 
3 2.7 
2
2 
   1   3        3            RSV Vehicle 0 0 
   2   4        2            RSV 
ALX-0171 
0.3 mg/kg 
0.3 0.3 
   3   3        3            RSV 
ALX-0171 
3 mg/kg 
3 2.9 
3
3 
   1   5        5            Mock Vehicle 0 0 
   2   6       5            Mock 
ALX-0171 
0.3 mg/kg 
0.3 0.2 
   3   5       5            RSV Vehicle 0 0 
  4   6       6            RSV 
ALX-0171 
0.3 mg/kg 
0.3 0.3 
 
On day 0 all lambs in study 1, study 2 and study 3 (except group 1 and 2) were infected 
with RSV Memphis 37 strain by the inhalation route whereas uninfected control lambs (study 3 - 
groups 1 and 2) received nebulized cell-conditioned media as described above. ALX-0171 
treatment started either on Day 1 (study 1) or Day 3 (study 2 and 3) post-infection and was 
repeated daily until Day 5 post-infection. In total, four lambs were excluded from the studies on 
various days post-infection because of secondary bacterial infections. Two lambs were from 
study 2 group 2, one lamb was from study 1 group 4 and one lamb was from study 3 group 2. On 
day 6 post-infection, all other lambs were euthanized with an intravenous injection of sodium 
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pentobarbital (Beuthanasia®, Schering-Plough Animal Health Corporation) overdose (1 mL/5 
kg). During necropsy, tissue samples were collected from each lung lobe of all animals in the 
same manner, with uniform sampling of each lobe.  
Preparation of hRSV Memphis 37 Virus Stock 
Memphis 37 (M37) RSV is a wild type RSV-A, first isolated from a 4 month old infant 
[20] and used in human clinical studies [21-24]. HEp-2 cells were infected in 300 cm2 flasks at 
0.5-1 multiplicity of infection (MOI) at a confluence of 80-90% by applying 4-5 mL of hRSV 
stock (Memphis 37 hRSV that was used originated from Meridian LifeScience, Memphis, TN, 
USA). Usually within 48-60 hours abundant syncytia appeared and close to 100% CPE was 
reached (as ascertained by periodic inverted microscope inspections). The monolayers of cells 
were then scraped off the bottom of each 300 cm2 flask using a large rubber policeman (sterile 
plastic tool commonly used for cell scraping). The collected cell solutions were transferred to 
polypropylene 15 mL conical centrifuge tubes (~1 tube per 300 cm2 flask), vortexed for 10 
seconds at high speed and centrifuged at 2500 rpm (~1260 x g) for 10 minutes. Supernatants 
were then collected from each tube and kept in separate tubes while each resulting pellet was 
resuspended in 5 mL of PBS pH 7.4. Each cell pellet sample was then sonicated for 5 x 2-second 
pulses with 5 seconds in between (to avoid overheating samples) using a tip-style sonicator 
(Sonic Dismembrator Model 500, FisherScientific) with a pre-sterilized tip (tip was pre-soaked 
in 70% ethanol for 10 minutes followed by air-drying). Sonicated samples were then centrifuged 
again at 2500 rpm (~1260 x g) for 10 minutes and the resulting supernatants were added to each 
of the corresponding supernatants collected initially. The samples were then diluted with a 
solution of 60% sucrose, 10% FBS in PBS to obtain 20% w/v total sucrose concentration which 
was shown to be beneficial in preserving virulence post freeze-thaw and post-nebulization [25]. 
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The titer of virus was subsequently determined, after one freeze-thaw cycle at -80°C, in a small 
portion of the resulting stocks that were aliquoted into cryovials for this purpose using the 
infectious focus forming unit (FFU) assay. The remainder of the stock was frozen/stored at -
80°C until needed for use in the lambs.The Memphis 37 RSV strain used in this study was 
passaged 6 times on Vero cells, then twice on HEp-2 cells.  Sucrose was added to 20% and the 
virus stock was frozen at −80°C and titered for infectivity on HEp-2 cells as has been 
characterized previously in this model [25].   
Monitoring of Clinical Parameters 
Lambs were monitored daily for body weight, rectal temperature, heart rate and percent 
blood oxygenation measurements (PalmSAT
®
 2500A VET pulse oximeter, Nonin Medical Inc., 
Plymouth, MN, USA), and manual heart and respiratory rates (by auscultation). Increased 
expiratory effort (forced expiration) was scored daily as were animal “wheeze” scores, using 
criteria previously reported [26].  
Blood Collection 
Approximately 1-1.5 mL of blood (at least 500 µL of plasma) was drawn from the 
external jugular vein with a syringe, and placed in spray coated K2EDTA vacutainer tubes. The 
fur at the sampling site was shaved and extensively washed prior blood withdrawal to avoid any 
contamination of deposited ALX-0171. The blood samples were then centrifuged at 1,600 x g for 
10 min at 4°C in order to obtain plasma. Samples were stored at ≤ -60°C prior to analysis. 
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Collection of Bronchoalveolar Lavage Fluid (BALF) 
Following euthanasia the lungs of each lamb were removed and each left and right lung 
was separated and weighed. BALF was collected and processed from the right lung lobe as 
previously described [26]. 
Gross Lesions Evaluation and Scoring 
Following euthanasia, the thorax was opened and the heart and esophagus were removed 
from the lungs. The percentage parenchymal involvement of gross hRSV lesions was scored for 
each individual lung lobe. The percentage of a specific lobe tissue that was affected by RSV in 
relation to the overall lobe tissue being scored was estimated. Mean percentage averages per lobe 
were calculated for each day of necropsy. 
Histologic Lung Evaluation and Scoring  
A histologic score was determined by evaluating percent involvement. This histologic 
score is an overall score based on the percentage of lung involvement in areas with hRSV 
lesions. Alveolar consolidation was defined by reduced expansion of alveolar lumen due to 
alveolar septal infiltration of neutrophils, lymphocytes, plasma cells, and type II cell hypertrophy 
along with intraluminal accumulation of neutrophils, macrophages, and small amounts of cell 
debris. The score was defined by converting the observed percentage ranges to a simple integer 
based consolidation scale: 0% consolidation = 0, 1-9% consolidation = 1, 10-39% consolidation 
= 2, 40-69% consolidation = 3, 70-100% consolidation = 4. Group averages were calculated for 
the alveolar consolidation score. In addition to the alveolar consolidation score, bronchitis, 
bronchiolitis, neutrophil infiltration, peribronchiolar and perivascular infiltration of lymphocytes, 
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syncytial cell formation, and epithelial alterations were also individually scored as previously 
published [26]. 
Immunohistochemistry for Viral Antigen Detection 
Immunohistochemistry for the detection of RSV antigen was performed on 5 µm-thick 
formalin-fixed paraffin-embedded (FFPE) lamb lung tissue sections taken from the right and left 
cranial, left middle, and left caudal lung lobes of each animal in accordance with methods 
published previously [26]. 20 unique 10X fields on each slide (containing two lung sections 
each) were assessed for RSV antigen staining by counting positively-stained cells within 
bronchioles and alveoli. The mean number of stained bronchi/bronchioles and alveoli per field 
were counted. 
Reverse Transcription Polymerase Chain Reaction (RT-qPCR) Assessment of RSV RNA 
Expression Levels in Lamb Lung Tissue. 
For each animal, tissue samples from right and left cranial, left middle and left caudal 
lung lobes (0.3-0.4 g of each lobe) were homogenized for total RNA isolation in TRIzol 
(Invitrogen), assessed for quantity and purity by spectrometry, and then RT-qPCR was 
performed using a One-Step Fast RT-qPCR kit master mix (Quanta, BioScience, Gaithersburg, 
MD) in a GeneAmp 5700 Sequence Detection System (Applied Biosystems, Carlsbad, CA) with 
PREXCEL-Q for all set up calculations as previously described [27, 28]. Primer and probe 
sequences for all targets were designed with ABI Primer Express 2.0, and have been used 
previously [27, 28]. All samples were diluted to achieve a final RT-qPCR concentration of 0.784 
ng/µL. Thermocycling conditions were 5 minutes at 50°C; 30 seconds at 95°C; and 45 cycles of 
3 seconds at 95°C and 30 seconds at 60°C. Samples and standards were assessed in duplicate, 
and each target gene quantification cycle (Cq) value was converted to a relative quantity (Qr) 
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based on each target’s standard curve using: Qr = EAMP
(b-Cq), wherein “b” and “EAMP” are the y-
intercept and exponential PCR amplification value, respectively. EAMP values were obtained 
from the slope (m) of each target standard curve by:  EAMP = 10
(-1/m)
, and all Qr values 
interpolated from standard curves were normalized to total lung RNA per RT-qPCR. No-RT 
control (NRC) reactions gave either no signal or generated Cq values greater than 13 cycles later 
than those in the corresponding RT-qPCR target reactions. 
Reverse Transcription Polymerase Chain Reaction (RT-qPCR) Assessment for RSV RNA 
in Bronchoalveolar Lavage Fluid  
Viral RNA was quantified by reverse transcription quantitative polymerase chain reaction 
(RT-qPCR) in BALF obtained from the right caudal lung lobe of each animal at necropsy as 
previously described [26]. RT-qPCR for RSV was then carried out as described above. 
Focus Forming Unit Assay 
Viral titers in bronchoalveolar lavage fluid (BALF) from the right lung caudal lobe were 
determined using an infectious focus assay (FFU) on HEp-2 cell monolayers as previously 
described [26]. 
Quantification of Urea in BALF and in Plasma 
Quantification of urea in both plasma and BALF was done using the QuantiChrom® 
Urea Assay Kit (BioAssay Systems) according to the manufacturer’s instructions. The method 
was validated specifically for lamb BALF and plasma. During urea sample analysis, the 
calibrator inter-curve precision did not exceed 4.1% and the intercurve accuracy was between -
3.2% and 2.3%.The inter-assay precision of the QC samples did not exceed 2.4% and the inter-
assay relative error was between -1.9% and 1.6% for plasma and BALF combined. 
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Quantification of ALX-0171 in BALF and Plasma 
Plasma samples from hRSV-infected lambs were treated by UV-irradiation for 1 hour in 
a biosafety cabinet prior to analysis in the ELISA. During qualification of the assay it was 
demonstrated that this treatment did not affect the accuracy of ALX-0171 determination in 
plasma. For BALF samples ALX-0171 quantification was performed in a biosafety cabinet. 
Qualified ELISA methods were used for the quantification of ALX-0171 in lamb plasma and 
BALF, respectively. In brief, an anti-Nanobody Nanobody (Ablynx) for plasma or a Nanobody 
specific mouse monoclonal antibody generated against ALX-0171 (Ablynx) for BALF were 
coated overnight on a 96 well Maxisorp plate (Nunc). Samples were applied on the coated plate 
and ALX-0171, present in the sample, was detected with a biotinylated monoclonal antibody 
generated against ALX-0171. This mAb was then detected by horseradish peroxidase (HRP) -
labeled streptavidin (Thermo Scientific). Bound streptavidin-HRP was revealed by adding 100 
µl/well of soluble high-sensitivity tetramethylbenzidine (s(HS)TMB; SDT Reagents) for 15min, 
followed by 1N HCl. The absorbance was read at 450 nm using a spectrophotometer, and the 
reference wavelength was 620 nm. The sensitivity of the ELISA methods was 21.5 ng/mL and 
10.7 ng/mL in plasma and BALF, respectively. During ALX-0171 sample analysis, the calibrator 
inter-curve precision did not exceed 4.5% and the intercurve accuracy was between -4.8% and 
1.7%.The inter-assay precision of the QC samples did not exceed 14.2% and the inter-assay 
relative error was between -6.9% and 6.6% for plasma and BALF combined 
Calculation of ALX-0171 Concentration in Lung Epithelial Lining Fluid (ELF) 
The ALX-0171 concentration in the epithelial lining fluid at necropsy was calculated 
based on the ALX-0171 concentration measured in BALF and following normalization by the 
Urea method [29]. The urea concentration in BALF was first corrected for possible 
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contamination with urea from blood using the method described previously [30, 31]. The 
concentration of ALX-0171 in epithelial lining fluid was calculated as described in different 
studies [30-33] using the following formula: ELF[ALX-0171] = BALF[ALX-0171] X 
([UreaPlasma]/[UreaBALF Corr]). Where: ELF[ALX-0171] is the ALX-0171 concentration in epithelial 
lining fluid, BALF[ALX-0171] is the ALX-0171 concentration in recovered BALF, [UreaPlasma] is 
the concentration of urea in plasma and [UreaBALF Corr] is the corrected urea concentration in 
BALF. 
Statistical Analysis 
All results were analyzed and interpreted using methods appropriate for the type of 
response analyzed. All statistical analyses were performed using SAS 9.4. Methods used and 
interpretation of outcome (e.g. statement on significance including significance level as a p 
value) are given in the text or in the caption of figures. 
 
Results 
Pharmacokinetics of ALX-0171 in Neonatal Lambs 
In all three of the performed studies blood samples were taken at selected time points 
following the first dose and all the subsequent doses for pharmacokinetic purposes. On Day 6, 
bronchoalveolar lavage fluid (BALF) sampling was performed post-mortem for PK analysis in 
the lung compartment. Once daily administrations of ALX-0171 via inhalation for 5 (Figure 1) 
or 3 (Figure 2) consecutive days resulted in high concentrations of ALX-0171 in lung epithelial 
lining fluid (ELF). A dose-dependent increase in ELF concentrations was seen on day 6. All the 
assessed lambs had quantifiable ALX-0171 concentrations with the notable exception of lamb 
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number 10 from the 1 mg/kg ALX-0171-treated group. This lamb had ALX-0171 levels that 
were below the quantification limit. The reason for this is unknown but an inadequate BALF 
retrieval cannot be excluded. This particular lamb, however, had been adequately exposed to 
ALX-0171 as shown by the systemic profile. Plasma ALX-0171 concentrations were roughly 3 
log lower than those observed in the lung compartment following pulmonary delivery to neonatal 
lambs (Figure 1and Figure 2). The systemic pharmacokinetics was linear with dose and time and 
the clearance was dependent on the animal weight. Although no intravenous data are available 
from neonatal lambs for ALX-0171, it is likely that absorption is also the driving force of ALX-
0171 pharmacokinetics in lamb.  
Effect of Daily ALX-0171 Administration to Neonatal Lambs When Started on Day 1 Post-
Infection 
To assess the therapeutic efficacy of ALX-0171 when administered by inhalation, 
thirteen lambs were inoculated with RSV on day 0. The day after infection (day 1), the lambs 
were randomized in either the placebo group or in one of the three ALX-0171 dose groups 
(Table 1) and were treated daily by inhalation for 5 consecutive days. Lambs underwent daily 
physical examinations and body weights, heart rates, rectal temperatures, respiratory distress and 
RSV-infection related symptoms were recorded. On day 6, the animals were euthanized and lung 
lavage samples as well as lung tissues were obtained for analysis of viral load in lung, 
histopathology and immunohistochemical analysis.  
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Figure 1. Pharmacokinetics study 1. Mean plasma concentration-time profiles of ALX-0171 (left 
graph) and ALX-0171 concentrations in epithelial lung lining fluid (ELF) (right graph) after five 
consecutive daily administrations by inhalation to neonatal lambs. ALX-0171 concentrations in 
ELF were derived from concentrations measured in BALF, which was sampled postmortem, 
after normalization for dilution based on the Urea correction method [29] (values were red blood 
cell corrected). Bronchoalveolar lavage fluid (BALF) was sampled 24 hours after the last dose. 
Results are expressed as mean ± standard error for plasma curves and as individual lamb results 
with mean indicated as horizontal line for ELF. The hatched line represents the lower limit of 
quantification (LLOQ) of the assay. *ALX-0171 levels were below quantification limit for lamb 
N°10 from the mid-dose group. 
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Figure 2. Pharmacokinetics study 2 and 3 combined. Mean plasma concentration-time profiles of 
ALX-0171 (left graph) and ALX-0171 concentrations in epithelial lung lining fluid (ELF) (right 
graph) after three consecutive daily administrations by inhalation to neonatal lambs for studies 2 
and 3 combined. ALX-0171 concentrations in ELF were derived from concentrations measured 
in BALF, which was sampled postmortem, after normalization for dilution based on the Urea 
correction method [29] (values were red blood cell corrected). BALF was sampled 24 hours after 
the last dose. Plasma ALX-0171 concentrations that were below the lower limit of quantification 
were excluded from the analysis and the results are expressed as mean ± standard error. The 
hatched line represents the lower limit of quantification (LLOQ) of the assay. ALX-0171 
concentrations in ELF are shown for each individual lamb with the mean indicated as horizontal 
line. 
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 hRSV inoculation by inhalation resulted in robust infection in all the analysed lambs as 
confirmed by RT-qPCR performed on BALF and lung tissue (Table 2). 
Table 2. Lung viral loads in hRSV infected neonatal lambs for the three performed studies 
$
Inhaled dose is defined as the total nebulised drug reaching the nose of the lamb (ie nebulised volume x 
concentration of ALX-0171 x 0.11 divided by body-weight). 
UD: Undetected foci 
Note:The mean number of focus forming units (FFU) and the RNA copies were calculated on the log10 scale as 
these parametere are known to be lognormally distributed. The limit of quantification of the FFU assay was 5 
FFU/mL or 0.7 log10 FFU/mL. For descriptive statistics 0 foci (i.e. undetectable virus) were counted as 0.7 log10 
FFU/mL of BALF.  
For the cultivatable viral titers in lung no statistical analysis was performed because all but 1 observations in the 
ALX-0171-treated groups were below the limit of quantification. For viral RNA data an ANOVA type model was 
used for statistical analysis where dose was a categorical variable. Correction for multiple testing was performed 
using the Hommel procedure. *p<0.05,  **p<0.01, ***p<0.0001  
 
In the placebo-treated lambs, RSV infection induced gross and microscopic lung lesions. 
Gross lung lesions were typical of experimental hRSV infection and consisted of locally 
extensive dark plum-red foci of pulmonary consolidation on each lung lobe which ranged from 
8.3% to 13.3% (mean percent consolidation per lung of 11.7%). Microscopic examination of 
Study 
ALX-0171 
target 
inhaled 
dose$ 
 
Viral load (BALF) 
 
Viral load (lung tissue) 
Viral culture 
(log10 FFU/mL 
± SEM) 
Reduction versus 
placebo (log10 
FFU/mL) 
RT-qPCR  
(Log10 viral 
RNA copies/mL 
± SEM) 
Reduction versus 
placebo (Log10 
viral RNA 
copies/mL) 
 
RT-qPCR  
(Log10 viral RNA 
copies/mg lung ± 
SEM) 
Reduction versus 
placebo (Log10 viral 
RNA copies/mg 
lung) 
1 
Placebo 4.49 ± 0.43 NA 6.39 ± 0.10 - 
 
6.02 ± 0.13 - 
0.3 mg/kg UD - 4.57 ± 0.16 1.82*** 
 
4.82 ± 0.17 1.21** 
1 mg/kg UD - 4.95 ± 0.09 1.44*** 
 
5.19 ± 0.36 0.83* 
3 mg/kg UD - 4.60 ± 0.06 1.79*** 
 
4.14 ± 0.16 1.88** 
2 
Placebo 4.83 ± 0.04 - 7.15 ± 0.20 - 
 
7.63 ± 0.07 - 
0.3 mg/kg UD (0.7) 4.13 5.90 ± 0.14 1.25* 
 
5.79 ± 0.21 1.84*** 
3 mg/kg UD (0.7) 4.13 7.01 ± 0.18 0.14 
 
7.09 ± 0.11 0.54* 
3 
Placebo 4.98 ± 0.41 - 7.26 ± 0.30  
 
5.47 ± 0.21  
0.3 mg/kg 0.87 ± 0.17 4.11 6.71 ± 0.25 0.55 
 
5.00 ± 0.24 0.47 
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lung tissue revealed the presence of locally extensive alveolar consolidation with mild epithelial 
necrosis in multifocal bronchioles, syncytial cell formation, infiltrates of neutrophils into the 
bronchiolar lumens, peribronchiolar infiltrates of lymphocytes and plasma cells and multifocal 
bronchioles had mild to moderate hyperplasia of epithelia. RSV antigen, assessed by 
immunohistochemistry, was present in areas with lesions and was localized to epithelial cells 
lining the bronchi, bronchioles and the alveoli as well as the cytoplasm of occasional 
macrophages. These gross and microscopic lesions and RSV antigen distribution were consistent 
with those observed previously in a study assessing hRSV kinetics in lambs [26]. 
Treatment of lambs with ALX-0171 at all three doses resulted in significant reductions in 
viral RNA titers that ranged from 1.44 to 1.82 Log10 viral RNA copies/mL in BALF (p<0.0001) 
and between 0.83 to 1.88 Log10 viral RNA copies/mg in lung tissue (p=0.035 and p=0.003, 
respectively) depending on the dose (Table 2). All treated lambs had undetectable cultivatable 
virus however, during staining of the foci, instead of using the polyclonal antibody (Goat 
polyclonal Ab to hRSV [all antigens]) a monoclonal antibody was mistakenly used (Mouse anti 
Fusion protein Meridian MAb to hRSV Fusion Protein, Cat. No. C87610M 1 mg/mL, Clone: 
RSV 3216 [B016]). This tool was shown to compete with ALX-0171 binding and was not used 
in subsequent assays and studies.  
Consistent with these reductions in viral loads, gross lung lesions were absent in all 
ALX-0171 treated lambs (Figure 3A) and microscopic alveolar consolidation scores were 
significantly reduced (p<0.0001, Poisson regression) following treatment (Figure 3B). Only in 
lamb number 10, from the 1 mg/kg ALX-0171-treated group, was there observable alveolar 
consolidation (score of 0.5). The mean number of bronchi/bronchioles and alveoi per field in 
which viral antigen was detected was also significantly reduced (p=0.007) (Figure 3C). Lamb 10 
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had the highest viral antigen expression although levels remained well below those seen in the 
placebo-treated lambs. Two lung lobes from this lamb showed some consolidated areas. Grossly 
and microscopically, this lamb also had lesions in these lobes that were not consistent with hRSV 
infection but, rather, bacterial infection. This lamb was not excluded from analysis because (i) 
the bacterial cause was not confirmed, (ii) systemic PK profiles indicated that this lamb had been 
adequately exposed, (iii) no other findings were seen and (iv) only regions (a minority of the 
surface area) of the lung had these lesions.  
Clinically, each clinical sign was individually scored which may not be the best measure 
for the severity of disease as it was shown that single clinical signs do not correlate well with the 
degree of dyspnoea and airway narrowing in acute wheeze in human infants [34]. In infants with 
acute respiratory infections, clinical scoring usually relies on a combination of clinical symptoms 
and signs (feeding intolerance, medical intervention, respiratory difficulty, respiratory frequency, 
apnoea, general condition, fever) [34]. For this reason, an exploratory composite clinical score 
was calculated post-hoc for each lamb in the post-treatment initiation period. The clinical 
parameters included in the clinical score were changes in blood oxygenation levels, body 
temperature and respiratory rates; presence or absence of expiratory effort and wheeze. Each of 
these parameters were either scored 1 or 0 based on pre-defined criteria (see Figure 3) with a 
possible maximal clinical score of 6. The hRSV-infected, placebo-treated lambs displayed 
increased clinical scores throughout the post-treatment initiation period (Figure 3D) with 3 out of 
3 lambs having a score of ≥1. These increased clinical scores were mainly driven by labored 
breathing as expiratory effort was apparent on day 6 post-infection in 2 out of 3 lambs 
(maximum score of 2) but was absent on other days (except on day 0 where 1 lamb displayed 
expiratory effort). Wheeze was absent in all placebo-treated lambs throughout the study. 
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Respiratory rates in the placebo-treated lambs increased on day 3 post-infection and reached a 
peak on day 4 with a mean of 66 breaths/min (% increase of 18.3% versus day 0). In the ALX-
0171-treated lambs 6 out of 9 (67%) lambs had a score of 0 and 3 lambs had a score of 1. Neither 
expiratory effort nor wheeze were detected at any time during the study in the ALX-0171-treated 
lambs whilst mean respiratory rates remained constant throughout the study where the mean 
respiratory rates on day 4 in the high-dose group was 56 breaths/min (% increase of 5.7% versus 
day 0). In the 3 lambs with a clinical score of 1, the relative body weight change between day 0 
and day 6 ranged from -2% to 17%. When considering mean body weight evolution of all lambs 
throughout the study duration there were no significant differences in amongst the groups.  
Delayed ALX-0171 Treatment Start to Day 3 Post-Infection Effectively Reduces Infection 
Related Changes 
Following the first study, 2 additional studies were performed to evaluate the therapeutic 
activity of ALX-0171 when administered close to the viral peak and onset of symptoms. In study 
2, 2 tested dose levels from the previous study were used. Based on the results of study 2, the 
lowest tested dose was selected for study 3, where appropriate mock-infected control groups 
were included to evaluate safety and efficacy of ALX-0171. Clinical parameters of lambs in 
study 2 were assessed as in study 1. However, for study 3, the general health-status of the lambs 
was additionally scored daily and is referred to as malaise score. This additional evaluation was 
included because of the observed variability in clinical parameters observed in study 1 and 2 
which seemed to be associated with a more intense sampling regimen (multiple timepoint blood 
draws, holding the animals during respiratory rate auscultations, possible use of smaller rooms 
during housing etc). The procedure to observe the lambs was adapted in study 3 which involved 
observing the lambs for increased periods of time without picking them up to make the 
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behavioural clinical assessments and respiratory rate assessments and by reducing the blood 
sampling to only 3 over the 6 days.  
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Figure 3. Gross lesions, histopathology lesions, immunohistochemical determination of viral 
antigen distribution and clinical scores summarizing clinical findings in lambs of Study 1. Gross 
and microscopic scores of lungs from hRSV-infected lambs treated with either placebo or ALX-
0171 from study 1. (A)  Viral-related lung gross lesions were scored and percentage 
parenchymal involvement was estimated for each lung lobe. Mean percentage averages per lobe 
were calculated. Legend: Rt Cr = Right cranial lobe; Rt Mid = Right middle lobe; Rt Cd = Right 
caudal lobe; Acc = Accessory lobe; Lt Cr = Left cranial lobe; Lt Mid = Left middle lobe; Lt Cd = 
Left caudal lobe.  
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Figure 3. (continued) (B) Microscopic (histopathologic) alveolar consolidation score was 
determined as percent area of RSV lesions followed by conversion to an integer-based 
consolidation scale as described in materials and methods section. (C) RSV antigen expression in 
lung tissue was determined by counting the number of affected bronchi/bronchioles or alveoli 
per field. (D) Clinical scores for lambs in study 1. For each lamb relative changes from baseline 
(day 0) in body-weights, respiratory rates, body temperature and blood oxygen saturation levels 
were calculated for each day. The presence or absence of expiratory effort or wheeze at any day 
after start of treatment was recorded. Each of the parameters were given a score of 0 or 1 based 
on pre-defined criteria as follows: If body weight increase between day 0 and day 6 >20% - score 
0, if ≤ 20% - score 1; if body temperature increase >10% at any day post treatment start – score 
1, if ≤ 10% - score 0; if respiratory rates increase >10%  at any day post treatment start – score 1, 
if ≤10% - score 0; if blood oxygenation levels increase >10% at any day after treatment start – 
score 1, if ≤10% - score 0; if expiratory effort present at any day after treatment initiation – score 
1, if absent – score 0; if wheeze present at any day after treatment initiation – score 1, if absent – 
score 0. The clinical score was the sum of these individual scores with a maximum of 6. Results 
are expressed as mean ± standard error for panels (A) and (C); group averages with individual 
lamb scores are indicated by bullet points for panels (B) and (D). 
 
RSV-infected placebo-treated lambs from both studies had comparable lung viral loads to 
placebo-treated lambs from study 1 whereas mock-infected placebo-treated lambs from study 3 
had no detectable virus as expected.  Consistent with findings from study 1, RSV-infection 
resulted in the presence of gross and microscopic lung lesions which was paralleled by lung 
epithelial cell viral protein expression (Figure 4 and Figure 5) ALX-0171 treatment initiated on 
day 3 post-infection, reduced infectious virus titers by more than 4 Log10 FFU/mL at both tested 
doses. The effect on viral copy numbers was less pronounced as the reductions ranged from 
0.14-1.25 Log10 in BALF (p=0.6 and p=0.019, respectively) and 0.54-1.84 Log10 in lung tissue 
(p=0.017 and p<0.0001) in study 2 and 0.55 Log10 in BALF (p=0.2) and 0.47 Log10 in lung 
tissue (p=0.2) in study 3. Despite these more modest reductions in viral copy numbers, ALX-
0171 treatment significantly reduced microscopic alveolar consolidation score in both study 2 
and 3 (p<0.0001 for combined ALX-0171 treated groups versus placebo) as well as for most of 
the individually scored microscopic lesions (Figure 4B, Figure 5B, Figure 6B and Figure 7). 
Reductions in the number of bronchi/bronchioles and alveoli expressing viral protein were also 
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noted in RSV-infected ALX-0171 treated groups from both studies, albeit non-sgnificantly for 
study 2 (p<0.01 for study 3 for RSV-infected ALX-0171 treated group versus RSV-infected 
placebo-treated group) (Figure 4C and Figure 5C). Gross lung examination in treated lambs 
confirmed the antiviral effect of ALX-0171-treatment as mean percent lung consolidation was 
40.7% for the placebo-treated lambs compared to 0% and 7.6% for low and high ALX-0171 dose 
treated lambs in study 2 (Figure 4A). In study 3, the mean percent lung consolidation was 39% 
for the RSV-infected placebo-treated lambs compared to 4.9% in the RSV-infected ALX-0171 
treated lambs (Figure 5A and Figure 6A).  
Clinically, the hRSV-infected placebo-treated lambs in study 2 all had a clinical score of 
3. This increased clinical score was driven by labored breathing as expiratory effort was evident 
in all 3 lambs (expiratory score score of 1) in at least one occasion during the post-treatment 
initiation period (i.e. day 3 to day 6) and in 1 lamb on day 0. In contrast to study 1, wheeze was 
also present on day 0 (1 lamb), day 3 (in 1 lamb), day 4 (in 1 lamb) day 5 (in 3 lambs) and day 6 
(in 2 lambs) with a wheeze score of 3 on all occasions. In the ALX-0171-treated lambs, clinical 
scores were reduced compared to the placebo-treated lambs (Figure 4D) with 1 lamb scoring 0, 3 
lambs scoring 1 and 1 lamb scoring 2. Expiratory effort and wheeze were only present in 1 lamb 
in the low dose ALX-0171 group on day 3 (expiratory effort and wheeze score of 1 and 2, 
respectively) and wheeze was present in 1 lamb in the high ALX-0171 dose group on day 6 
(wheeze score of 1). Respiratory rates were relatively variable throughout the study duration with 
a mean relative change in respiratory rates from day 0 to day 6 for the placebo-treated lambs of 
23.3% ± 3.2% (mean ± se) in contrast to -10.6% ± 10.6% and -6.2% ± 9.4% for low and high 
ALX-0171 treated lambs, although this difference was not significant. 
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Figure 4. Gross lesions, histopathology lesions, immunohistochemical determination of viral 
antigen distribution and clinical scores summarizing clinical findings in lambs of Study 2. Gross 
and microscopic evaluation of lungs from hRSV-infected lambs treated with either placebo or 
ALX-0171 from study 2. (A)  Viral-related lung gross lesions were scored and percentage 
parenchymal involvement was estimated for each lung lobe. Mean percentage averages per lobe 
were calculated. Legend: Rt Cr = Right cranial lobe; Rt Mid = Right middle lobe; Rt Cd = Right 
caudal lobe; Acc = Accessory lobe; Lt Cr = Left cranial lobe; Lt Mid = Left middle lobe; Lt Cd = 
Left caudal lobe. (B) Microscopic (histopathologic) alveolar consolidation score was determined 
as percent area of RSV lesions followed by conversion to an integer-based consolidation scale as 
described in materials and methods section. (C) RSV antigen expression in lung tissue was 
determined by counting the number of affected bronchi/bronchioles or alveoli per field. (D) 
Lamb clinical scores. Clinical scores were calculated as described in Figure 3. Results are 
expressed as mean ± standard error for panels (A) and (C); group averages with individual lamb 
scores are indicated by bullet points for panels (B) and (D). 
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Figure 5. Gross lesions, histopathology lesions, immunohistochemical determination of viral 
antigen distribution and clinical scores summarizing clinical findings in lambs of Study 3. Gross 
and microscopic findings of lungs from mock-infected and hRSV-infected lambs treated with 
either placebo or ALX-0171 from study 3. (A)  Viral-related lung gross lesions were scored and 
percentage parenchymal involvement was estimated for each lung lobe. Mean percentage 
averages per lobe were calculated. Legend: Rt Cr = Right cranial lobe; Rt Mid = Right middle 
lobe; Rt Cd = Right caudal lobe; Acc = Accessory lobe; Lt Cr = Left cranial lobe; Lt Mid = Left 
middle lobe; Lt Cd = Left caudal lobe. (B) Microscopic (histopathologic) alveolar consolidation 
score was determined as percent area of RSV lesions followed by conversion to an integer-based 
consolidation scale as described in materials and methods section. (C) hRSV antigen expression 
in lung tissue was determined by counting the number of affected bronchi/bronchioles or alveoli 
per field. (D) Lamb clinical scores. Clinical scores were calculated as described in Figure 3. 
Results are expressed as mean ± standard error for panels (A) and (C); group averages with 
individual lamb scores are indicated by bullet points for panels (B) and (D). 
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Figure 6. Images of gross lesions and histopathology in Study 3. Lung pathology in mock-
infected or hRSV-infected lambs treated with either placebo or ALX-0171 from study 3. (A) 
Images of lungs from mock-infected lambs (left column) and hRSV-infected lambs (right 
column). Lambs were either treated with placebo (top row) or ALX-0171 (bottom row) for 3 
days consecutively. Images were taken at necropsy on day 6 post-infection. Lungs from lambs 27 
(tag ID 4514), 38 (tag ID 4500), 33 (tag ID 4513) and 44 (tag ID 4504) are shown. Viral lesions 
are visible as plum-red lesions in lamb 38. (B) Microscopic (histopathologic) lung lesions of 
hRSV infected lambs. Microscopic lung images are from the same lamb lungs shown in Figure 
6A.  There was no microscopic lung lesions seen in the mock-infected placebo and ALX-0171-
treated groups.  
 
 
A. 
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Figure 6. (continued) The mock-infected placebo-treated group picture contains a normal 
bronchiole lacking lesions, while the mock-infected ALX-0171-treated group has a bronchus 
with surrounding cartilage (fat arrow) also lacks lesions. The hRSV-infected placebo-treated 
group had a wide spectrum of lung lesions, with bronchitis characterized by the lumen which 
contains neutrophils (thin short arrow), sloughed epithelial cells (fat arrow), mucin (arrowhead), 
and red blood cells (long thin arrow). The hRSV-infected ALX-0171-treated group had 
significantly reduced histopathological lesions when compared to the mock-infected placebo and 
ALX-0171-treated groups, which was evident by the clear bronchi (circle), bronchioles (star) and 
alveolar spaces (diamond) present in the picture. 
 
 
 
 
Figure 7. Individually scored histologic lung lesions in neonatal lambs. Bronchiolitis, neutrophil 
infiltration, peribronchiolar and perivascular infiltration of lymphocytes, syncytial cell formation 
and epithelial alterations were individually scored for each lamb in the three performed studies 
following the criteria reported previously [26]. Results are expressed as mean ± standard error 
for each scored lesion. 
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In study 3, the hRSV-infected placebo-treated lambs and the mock-infected placebo-
treated lambs all had a clinical score of 1 due to variable increases in respiratory rates. No 
noticeable expiratory effort and wheeze was apparent in these lambs. All hRSV-infected 
placebo-treated lambs on day 2 post-infection demonstrated unremarkable/normal behavior, 
energy level, perambulatory activity, and were alert and interactive. By the next day, 4 out of 5 
hRSV-infected lambs clearly exhibited a decline in their general health status (Figure 8) On day 
4 and 5 all the hRSV-infected placebo-treated lambs displayed some degree of reduced general 
health status as they were more lethargic in their movements, less prone to interact with each 
other and, when standing or laying down, drooped their heads and ears downward and appeared 
to be in a generally weakened and/or depressed state. In contrast, none of the mock-infected 
lambs treated with placebo displayed an altered general health status throughout the study 
duration. Clincial scores in hRSV-infected ALX-0171-treated lambs were comparable to the 
mock-infected ALX-0171-treated lambs where 5 out of 6 lambs and 4 out of 5 lambs, 
respectively had a score of 1. As in the placebo-treated lambs, the only noticeable finding was 
variably increased respiratory rates. None of the mock-infected ALX-0171-treated lambs 
displayed an altered general health status over the study duration. In the ALX-0171-treated 
lambs, a decline in the general health status of 3 out of 6 lambs was apparent on day 3 only 
which was the first treatment day. On the next and all the subsequent days, all the ALX-0171-
treated lambs displayed normal behavior and general health status.  
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Figure 8. Malaise score study 3. Scoring of general health status of hRSV-infected lambs treated 
with either placebo or ALX-0171. General health status was assessed daily until day 5 post-
infection using the following scoring criteria: 0 - No clinical signs; 1 – Reluctant to move; 2 – 
Reluctant to move, head down, depressed, not interested in eating; 3 – Down, unwilling to get up 
or difficulty standing, not eating; 4 – Down and should be euthanized, probably cannot eat. 
Results are shown for each individual lamb and means are shown as bars.  
 
Discussion 
As there are no fully effective therapies for RSV infection, new approaches and 
therapeutic regimens are needed.  Although prophylactic treatment/prevention of RSV infection 
is helpful to individuals prior to RSV infection or very recent exposure to RSV, therapeutic 
efficacy in the face of RSV infection is even more useful and beneficial, because individuals 
often do not know that they have been exposed to RSV virus. This study assessed a novel 
therapeutic, ALX-0171, in neonatal lambs as a model for hRSV infection in infants. 
In vivo efficacy of ALX-0171 has been previously tested in the cotton rat (Sigmodon 
hispidus) [16]. Although semi-permissive to hRSV infection, cotton rat studies have proven 
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useful as both RSVIg (RespiGam®) and palivizumab (Synagis®) were advanced to clinical trials 
solely based on cotton rat data [9]. However, as the intended route of administration for ALX-
0171 is by inhalation, adequate drug deposition in the lung is a prerequisite for efficacy. Because 
drug deposition is strongly affected by breathing patterns (respiratory frequency and breathing 
volume) which is dependent on body size and airway anatomy [18], the translational fidelity of 
rodent studies in terms of dose setting will be of limited value. In contrast, the respiratory system 
of lambs and human infants share many anatomical, physiological and developmental features 
that increase the translational value of  studies performed in lambs for inhaled drugs [14, 18]. In 
addition, colostrum-deprived neonatal lambs are highly relevant for the study of RSV infection 
due to their natural susceptibility to ovine, bovine and human strains of RSV [27, 35, 36] and to 
the similarities in disease pathogenesis to that of human infants [12, 37]. This lamb RSV-
infection model therefore constitutes a valuable tool for use in pre-clinical studies of vaccines or 
therapeutics. 
Previous work in our laboratory has demonstrated that RSV-infection with Memphis 37 
strain in neonatal lambs results in robust viral replication in the lungs that peaks around day 3 
post-infection before subsiding by day 8. The viral replication was paralleled by an increase in 
RSV lung viral antigen expression, gross and histopathologic lesions and appearance of 
respiratory distress [12, 26, 27].  
In the herein described studies, the administration of nebulized ALX-0171 resulted in 
systemic exposures that were indicative of absorption dependent pharmacokinetics. Overall, no 
unexpected retention of ALX-0171 in studied tissues or organs was observed. No difference in 
ALX-0171 deposition was noted between RSV-infected and uninfected lambs, although subtle 
differences may have been masked by the observed variability. Local lung ALX-0171 
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concentrations attained were adequate for reducing clinical or illness score (malaise), gross and 
microscopic lung lesions, viral titers, viral antigen, and viral RNA levels, even when 
administered around the peak of viral replication.  
Previous studies have shown that RSV infects ciliated and bronchiolar airway epithelial 
cells in the respiratory tract [38-40] as well as type II pneumocytes [43, 44]. Consistent with 
these findings, viral antigen expression was present on these cell types in the hRSV-infected 
lambs with a significant correlation between hRSV expression in alveoli and bronchioles (Figure 
9A). ALX-0171, greatly reduced the viral antigen expression both in the bronchioles and alveoli, 
which is indicative of a decreased number of infected epithelial cells. This decreased viral 
antigen expression was correlated with the decreased gross viral lesions (Figure 9B-C) and 
decreased viral titers (Figure 9D-E). There was also a significant correlation between infectious 
virus titers and gross viral lesions (Figure 9F). 
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Figure 9. Correlation between independently scored readouts in hRSV – infected neonatal lambs. 
Correlation coefficient was calculated by Spearman's rank correlation test for the indicated 
parameters. Mock-infected lambs are excluded from the analysis. 
 
 Thus, measuring infectious virus titers in BALF could provide a reliable surrogate 
endpoint to monitor disease progression, at least in lambs. Similarly, viral loads were 
consistently correlated with increases in multiple different disease measurements (symptoms, 
physical examination, and amount of nasal mucus) in a human challenge study [21] and would 
seem to predict disease severity in previously healthy infants [41, 42]. ALX-0171 was less 
effective at reducing RSV RNA titers in lung tissue and BALF (as determined by RT-qPCR) 
than infectious virus titers as expected since ALX-0171 binds virus but does not directly inhibit 
transcription. Similarly, motavizumab, when given therapeutically to infants hospitalized with 
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RSV disease, resulted in a ≥2 Log10 PFU/mL decrease in cultivatable virus between day 0 and 
day 1. This reduction ranged from 0.3 to 1 Log10 PFUe/mL for viral transcripts over the same 
period [43]. Likewise, in our studies cultivatable virus was reduced by >4 Log10 FFU/mL on 
day 6 in the ALX-0171-treated lambs in comparison to the vehicle-treated lambs. On the same 
day viral RNA titers were reduced by 0.14 to 1.88 Log10 viral RNA copies/mL or mg in both 
BALF and lung tissue. The likely explanation of the difference between the two measures is that, 
on the one hand, RT-qPCR not only quantifies fully replication-competent viruses but also 
complete viral particles unable to replicate, partially assembled virions, and whole and 
fragmented viral genome [44], on which ALX-0171 has no effect. Consequently, the natural rate 
of viral load decline is less steep when using a RT-qPCR method than when using quantitative 
culture, which is likely to confound antiviral efficacy determination of test compounds targeting 
RSV [44, 45]. The culture assay, on the other hand, quantifies fully infectious particles, but it is 
conceivable that viral particles that are neutralized by ALX 0171 and that are still present in the 
respiratory tract would not be quantified in the culture assay whereas they would be quantified 
by RT-qPCR. The culture assay would thus reflect the fact that either less virus is present in a 
sample or that any virus still present is effectively neutralized. The positive effects of ALX-0171 
on the other viral related endpoints (viral antigen expression, gross lesions, histopathology) 
further substantiates the robust anti-viral effect of ALX-0171 in neonatal lambs. 
Clinically, in the hRSV-infected neonatal lambs, a decline in respiratory function and 
general health status was observed in the herein described studies with observable expiratory 
effort and wheeze in some lambs and increased respiratory rates. However, these observations 
were not consistently present in all lambs thus making the analysis of ALX-0171 effects on 
altering clinical signs difficult. The natural individual susceptibiliy of hRSV infection in the 
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lambs may explain part of this observation. Similarly, most clinicians recognize bronchiolitis as 
a constellation of clinical symptoms and signs [46] with a high heterogeneity in disease severity 
likely due to a combination of host and viral factors [47]. Study procedures may also explain part 
of the variability seen in the clinical parameters as the procedures for clinical assessments were 
adapted for study 3 allowing for increased observation times and more robust scoring of lamb 
behavioural changes. One important challenge in the performance of these studies was the 
minimisation of any cross-contamination between not only hRSV-infected and uninfected lambs 
but also of ALX-0171 and placebo treated lambs making full blinding of the evaluation of 
individual clinical parameters difficult. The need to objectivate as much as possible the effects of 
ALX-0171 on these clinical parameters and their observed heterogeneity, led to the devise of a 
composite clinical score taking into account blood oxygen saturation, respiratory rates, body 
weight gain, body temperatures, expiratory efforts and wheeze using pre-defined scoring criteria 
which were considered meaningful. All these parameters have been shown to be important in 
hRSV-disease both in animal models and infants [27, 34, 46, 48, 49]. This analysis showed that 
ALX-0171 treatment reduced the clinical severity and had a positive effect on general health 
status.  
In conclusion, when considering the totality of the results obtained from the studied effect 
measures (virology, observations of clinical signs, gross pathology and histopathology) which 
are known indicators of hRSV infection, a beneficial effect of ALX-0171 was noted on all 
established markers although the clinical and quantitative expression of hRSV infection differed 
somewhat in the different studies. Viral replication parameters were consistent with associated 
gross and microscopic lesions and viral antigen distribution. That is, in lambs not treated with 
ALX-0171, the high RSV titers and high levels of RSV RNA were associated with increased 
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severity of gross and microscopic lesions and viral antigen distribution. Following ALX-0171 
treatment, reduced RSV parameters were associated with reduced lesions and antigen.  There 
was no clear dose dependency seen which suggests that the lowest dose tested already provides 
full efficacy. ALX-0171 administered therapeutically may thus have the potential to be effective 
in the context of a developed hRSV infection in infants. 
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Abstract  
Rationale  
The aim of this study was to determine the clinical symptomology and sickness behavior 
of RSV infected lambs through clinical data and video recording, without the heavy sampling 
schedule that previous lamb studies have included. 
Methods  
  Colostrum-deprived newborn lambs were nebulized with M37 human RSV (infected) or 
cell-conditioned growth medium (control) at day 0, and were observed daily for general clinical 
signs of illness, and monitored for clinical data until day 8 p.i. Behavior data was collected by 
10-minute instantaneous scan sampling from video recordings using Noldus Observer software 
with researcher blind to treatment group, lamb and trial day. Data was analysed using 
generalized mixed models (GLIMMEX) to compare changes in response across trial days and 
between control and inoculated lambs. 
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Results  
                    General illness signs were sparse for the infected and non-infected groups.  Mean 
respiratory rates (RR) and body temperatures (BT) differed on days 1 p.i. (RR and BT) and 5 p.i. 
(BT). Expiratory effort was only observed for 2 lambs in the infected group on days 4 (n=2) and 
7 (n=1) p.i. Contrary to our hypothesis, infected lambs spent significantly less time lying and 
more time standing than control lambs. However, both treatment groups displayed tremoring and 
lameness, and bacterial pneumonias were observed at necropsy in the control group, confounding 
the clinical data and lamb behaviors due solely to RSV infection.   
Conclusion  
                 Clinical signs and sickness behavior in both groups were confounded by non-RSV 
clinical signs of tremors and lameness, as well as bacterial pneumonias. Bacterial infections are 
an inherent problem of the hRSV infection neonatal lamb model, and as long as they are present, 
interpretation of clinical data and lamb behaviors should be done with caution when drawing 
conclusions. Future lamb studies should make an effort to solely demonstrate RSV infection in 
lambs by identifying and preventing secondary or opportunistic pathogens.   
 
Introduction 
                  Human Respiratory Syncytial Virus (hRSV) is a major cause of respiratory disease in 
infants and young children in the United States and worldwide. Each year in the United States 
alone, more than 2 million children need medical intervention to treat the symptoms and 
complications of RSV infection [1, 2]. Clinical signs develop four to six days after infection with 
RSV, and usually subside after one to two weeks [3].  These signs vary with severity of disease 
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and range from mild flu-like symptoms (coughing, sneezing, fever, and loss of appetite) in 25% 
to 40% of first-time exposed infants to severe bronchiolitis with or without pneumonia (rapid 
breathing, difficulty breathing, and wheezing) necessitating hospitalization in 0.5% to 2% of 
infants [4]. In very young infants, irritability, decreased activity, and apnea may be the only 
symptoms of infection. These clinical symptoms together comprise the sickness behavior, and 
have been attributed to both the immune response to RSV, as well as the direct damage to RSV-
infected bronchiolar epithelium [5, 6]. 
                  Sickness behavior is an adaptive organized immune response that leads to 
physiological and behavioral changes that are manifested in animals commonly as fever, 
depression, decreased lipido, adipsia, anorexia, and decreased grooming and social interaction 
due to potentially injurious stimuli, such as microbial agents (e.g. virus, bacteria, fungal, 
parasites) [7-9]. This evolved behavioral response helps to conserve energy through lethargy and 
fatigue and fight bacterial and viral infections by increasing body temperature through fever [7].  
Important immune mediators that contribute to the sickness response include 
proinflammatory cytokines IL-1, IL-6, and tumor necrosis factor [7-10].  Together these 
cytokines are able to mediate local, systemic, and central nervous responses during acute and 
chronic infection that leads to sickness behavior [7]. However, fever can be metabolically 
expensive, and if prolonged animals may succumb to the disease, or become susceptible to 
predation [8, 9]. 
Sickness behavior can be easily induced and studied in animals with exposure to 
lipopolysaccharide (LPS) endotoxin. For example in rodents, fever, anorexia, and decreased 
activity and grooming are at their highest at increased lipopolysaccharide (LPS) endotoxin doses 
[11]. Therefore, sickness behavior varies with disease severity. This can also be seen in cattle 
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with mastitis and bovine respiratory disease, where the sickness behavior was greater for severe 
disease when compared to mild mastitis and bovine respiratory disease [12, 13]. Sickness 
behavior can be used to detect infected animals; however, identifying animals with mild disease 
and subclinical signs may be more challenging [14]. 
                  Using neonatal lambs to study RSV infection in human infants has proven to be a 
relevant animal model, with lambs having several biological features that closely mimic RSV 
infection in human infants. These similarities to human infants include lung development, lung 
structure and airway branching, cellular composition and immune responses, susceptibility to 
hRSV strains (Long, A2, and Memphis Strain 37), clinical symptomology, gross and histologic 
lesions, lung size to human infants, and the ability to obtain lambs lacking maternal antibodies 
[15-23].  These features are important for using RSV lambs to assess vaccines and antiviral drug 
safety and efficacy. 
                  Determining the clinical symptoms associated with hRSV infection in lambs has been 
challenging. Previous studies done in our laboratory group using different strains of RSV (A2, 
Memphis 37) have identified several clinical signs including fever, coughing, expiratory effort, 
and wheezing [15, 16, 17, 18, 24].  Clinical parameters such as respiration rate, heart rate, pulse 
oxymetry, and weight loss have not been statistically significant between RSV infected and non-
infected lambs. The only clinical sign that has been observed the most in lambs as a significant 
clinical marker to monitor for RSV disease is expiratory effort [16, 25-27]. Overall, clinical signs 
in lambs infected with RSV can be variable and non-predictable, and interpretation can be 
confounded by many variables that include the strain of RSV, experience of the interpreter 
observing clinical signs, handling of lambs, sampling schedule, experience in getting respiration 
and heart rate, unknown side effects of therapeutic drugs, administration of anesthetics, and 
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secondary bacterial infections. To add to this list, lambs are herd animals and don’t express clear 
signs of sickness until severe disease is present or near death. The aim of this study is to better 
define the clinical symptomology and sickness behavior of RSV infected lambs through clinical 
data and video recording of lamb behavior without the heavy sampling schedule that previous 
lamb studies have included.  
 
Material and Methods 
Experimental Design 
Fourteen colostrum-free neonatal lambs (1–2 days of age) numbered 1 through 14 
received daily antibiotics (Ceftiofur, Pfizer, New York, NY; 1–2 mg/kg, intramuscular) to 
prevent secondary bacterial infections. They were randomly assigned based on age and sex into 
two groups of seven, groups labeled 1 through 6, with the RSV infected group containing groups 
4, 5, and 6, and the non-infected group containing groups 1, 2, and 3. RSV infected and non-
infected groups were then placed into separate rooms, with the RSV infected group containing 
lambs numbered 8-14 and the non-infected group containing lambs 1-7. Groups 1, 2, and 3 
contained lambs numbered 1 and 2, 3 and 4, and 5, 6, and 7, respectively, with the infected 
groups having the same arrangement, 8 and 9 (group 4), 10-11 (group 5), and 12, 13, and 14 
(group 6). Each room contained two pens, with one pen containing two groups, and the second 
adjacent pen containing only one group. The RSV infected group had the first pen with groups 4 
and 5 and the last pen contained group 6, while the non-infected group had one pen with groups 
1 and 2, and the other with group 3. The pens that contained two groups of lambs were separated 
by a center divider with a communal heating lamp that did not hinder socialization. Two video 
recording cameras (non-audio) were strategically placed at each end of the pens to fully capture 
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the observations of the lambs over a 24 hour continuous period, beginning at day -1 through day 
8 post infection (p.i.), for a total of ten days (Figure 1). Each group contained one milk bucket 
with the nipples specifically positioned where the camera would be able to record the lambs 
feeding. Milk consumption was measured every day, starting at day 0 and ending at day 7 p.i. for 
each group. Each morning before feeding, clinical signs (general illness, cough, eye or nasal 
discharge, expiratory effort, wheezing, auscultated respiration, heart rate, temperature, and body 
weight) were collected after waiting 20-30 minutes for the lambs to settle down while being 
inside the room.  
 
Figure 1: Pen and video recording camera set up for both infected and non-infected rooms. Each 
pen contained two cameras at each end with a center divider and a communal heating lamp, and 
one milk bucket per pen group.  
At day 0, each nebulized group (RSV infected and non-infected) received either three 
successive 2-mL nebulizations of RSV M37 1.27 x 107 FFU/mL (in DMEM growth media + 
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20% sucrose w/v) or cell-conditioned growth media (DMEM + 20% sucrose) over a 23-minute 
period using a PARI LC Sprint™ nebulizer (PARI Respiratory Equipment, Inc., Lancaster, PA, 
USA) at 4L/min at 16 PSI (Philips Respironics Air Compressor, Andover, MA, USA) attached to 
a conical mask fitted with a round rubber diaphragm with a pre-cut center hole through which the 
nose and mouth of the lamb was inserted (MidWest Veterinary Supply, Inc., Burnsville, MN), 
respectively. Lambs were then euthanized by sodium pentobarbital overdose and necropsied at 
day 8 p.i. After euthanasia the thorax was opened, lungs were removed, and gross lesions were 
scored and photographed ex vivo. Tissue samples were collected from each lung lobe of all 
animals in the same manner, with uniform sampling of each lobe. Before lung dissection, 
bronchoalveolar lavage fluid (BALF) was collected from the right caudal lung lobe (in double-
modified Iscove's media (DMIM) for infectious Focus-Forming Unit (FFU) assay and RT-qPCR 
for M37. Three samples from each lobe were snap frozen in liquid nitrogen for reverse 
transcription quantitative polymerase chain reaction (RT-qPCR), and two samples from each 
lobe were placed in tissue cassettes and put in 10% neutral-buffered formalin for histological and 
immunohistochemical analyses. Animal use and experimental procedures were approved by 
Iowa State University’s Animal Care and Use Committee (IACUC).  
Monitoring of Clinical Signs 
Clinical signs were taken every morning before feeding and after waiting 20-30 minutes 
for the lambs to settle down while being inside the rooms of RSV infected and non-infected 
lambs. A clinical chart was developed to record clinical signs in order of less to more stressful, 
beginning with recording of general illness signs (Table 1), then followed by  cough, eye or nasal 
discharge (Table 2),  and expiratory effort (forced expiration) and wheezing (Table 3). Finally, 
respiration, heart rate, rectal body temperature, and body weights were taken, with all lambs 
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receiving a daily antibiotic (Ceftiofur, Pfizer, New York, NY; 1–2 mg/kg, intramuscular) at the 
end to prevent secondary bacterial infections. After observing lambs for general illness signs and 
collecting clinical data, lambs were fed.  
Table 1. Scoring criteria for general illness 
Score General illness score 
0 
 
No clinical signs 
1 Reluctant to move 
2 Reluctant to move, head and ears down, not interested in eating 
3 Down, unwilling to get up or difficulty standing, not eating, +/- isolated 
4 Down, isolated, not eating, and should be euthanized 
 
Table 2. Scoring criteria for cough and ocular/nasal discharge 
Score Cough Eye or nasal discharge 
0 No cough No discharge 
1 
Occasional cough (once/5 
minutes) 
Earliest detectable watering 
2 
Repeated cough (more than 
once/5 minutes) 
Consistent watering 
3 
Repeated, harsh cough, 
dyspnea 
Copious watering 
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Table 3.  Scoring criteria for lung function by auscultation 
 
 
 
 
 
 
 
Auscultation of Respiration and Heart Rate 
The lungs were first auscultated for expiratory efforts and wheezing. Respiratory rates 
were then calculated by auscultating the lungs and counting breaths for 15 seconds and then 
multiplying the number of breaths by 4 to get breaths per minute (bpm). Heart rates were also 
taken and calculated in the same manner by auscultating the heart to get beats per minute (bpm).  
For both respiratory and heart rates, lambs were held gently in place standing up in their pen 
without picking them up.  
Milk Consumption 
Milk consumption was measured at the pen level every morning before feeding from day 
0 through day 7 p.i. for both RSV infected and non-infected groups.  The amount of milk given 
for each day (morning, mid-day, and evening) was based on the number of lambs in each group 
and their body weight of that morning. Milk consumption for each day was calculated by 
Score 
Expiratory efforts 
 
Wheezing 
(High-pitched whistling sound made while 
breathing) 
0 No expiratory effort No wheeze 
1 
Earliest detection of 
increased expiratory effort 
Earliest detectable wheeze by auscultation 
2 
Moderate expiratory effort 
(>1 sec) observed with some 
abdominal effort 
Audible wheeze in all lung fields by 
auscultation 
3 
Expiratory effort (>3 
sec)with hard abdominal 
effort 
Wheeze audible without stethoscope 
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subtracting the milk that was left in the bucket from the previous night that morning from the 
total amount of milk given for that day. 
Behavioral Observations 
Video recording of lambs occurred between 6:30 and 18:30 on days 0 through 7, relative 
to inoculation. Video was captured using two Noldus portable labs (Noldus Information 
Technology, The Netherlands), one in each of the treatment rooms. Cameras were placed in one 
corner of each pen (WV-CP484, Matsushita Co. Ltd, Kadoma, Japan), approximately 7 feet 
above the pen flooring (Figure 1). The cameras were connected to a multiplexer, which allowed 
the images to be recorded digitally onto a PC using HandiAvi (v4.3, Anderson’s AZcendant 
Software, Tempe, AZ) at 30 frames/s. 
Behavioral observations were collected using instantaneous scan sampling every 10 
minutes beginning at 6:30 and ending at 18:30 [28]. All observations were collected by one 
trained technician blinded to animal ID, treatment and trial day (intra-observer reliability was 
98%) using The Observer® software (Ver. 10 Noldus Information Technology, Wageningen, 
The Netherlands). Training consisted of familiarizing the technician with the ethogram and the 
software using representative video segments (Table 4). Once inter-observer reliability of 90% of 
achieved relative to experienced laboratory personnel, the technician commenced with formal 
data collection. A neutral technician performed the blinding procedures for the video recordings 
for all tests. The blinding procedures involved assigning a random number to each video and 
sorting for the purpose of providing a random sequence in which videos were to be scored. Five 
videos were selected at random and duplicated within the sequence for the purpose of 
determining intra-observer reliability. Behavior frequencies were summed for each trial day and 
subsequently analyzed. 
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Table 4. Ethogram used to evaluate lamb behavior following respiratory syncytial virus or 
control treatment 
Behaviors Behavior Description Modifier 
Feeding 
Head within 2 inches of and oriented towards the milk 
bucket  
Locomotion/Active 
Weight bearing on all four limbs and moving head and/or 
limbs  
Standing Weight bearing on all fours limbs and stationary 
Social
1
/Isolated
2
 
Lying Belly and torso touching the ground Social
1
/Isolated
2
 
1
 Social: ≤1ft from pen mate and/or lambs in adjoining pen 
2
 Isolated: >1ft from pen mate and/or lambs in adjoining pen 
 
Virus  
M37 hRSV is a wild type RSV-A first isolated from infected humans and used in human 
clinical studies [25]. The Memphis 37 RSV strain used in this study was passaged 6 times on 
Vero cells then twice on HEp-2 cells. Sucrose was added to 20% and the virus stock was frozen 
at −80°C and titered for infectivity on HEp-2 cells.  
Gross Lesions Evaluation and Scoring  
Following euthanasia, the thorax was opened and the heart and esophagus were removed 
from the lungs. The percentage parenchymal involvement of gross RSV lesions was scored for 
each individual lung lobe, and if present, the area and amount of lung lobes affected by bacterial 
pneumonia was also recorded. The percentage of a specific lobe tissue that was affected by RSV 
in relation to the overall lobe tissue being scored was estimated based on a score as done 
previously [16]. The percent total involvement of all lung lobe lesions was calculated by adding 
up estimated percentages of gross lesions given to each lung lobe and dividing by 7, which is the 
number of lung lobes present in lambs.    
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Histologic Evaluation and Scoring 
A histologic score was given by determining percent involvement followed by 
conversion to an additional integer-based consolidation scale used by our laboratory previously 
[13] wherein: 0% consolidation = 0; 1%-9% consolidation = 1; 10%-39% consolidation = 2; 
40%-69% consolidation = 3; 70%-100% consolidation = 4. Group averages were calculated for 
the alveolar consolidation score. In addition to the consolidation score, bronchitis/bronchiolitis, 
neutrophil infiltration, peribronchiolar and perivascular infiltration of lymphocytes, syncytial cell 
formation, and epithelial alterations were also scored according to criteria previously reported 
[16]. 
Immunohistochemistry 
Immunohistochemistry for detecting RSV antigen was performed on 5 µm-thick 
formalin-fixed paraffin-embedded (FFPE) lamb lung tissue sections taken from the right and left 
cranial, left middle, and left caudal lung lobes of each animal in accordance with methods 
published previously [16]. Primary polyclonal goat anti-RSV (all antigens) antibody (EMD 
Millipore Corporation, Billerica, MA, USA) was applied for 90 minutes at room temperature 
diluted 1:500 in TBS-tween containing 10% NSS and 3% BSA. After rinsing with TBS-tween, 
biotinylated rabbit anti-goat secondary antibody (Kirkegaard-Perry Labs, Gaithersburg, MD, 
USA) diluted 1:300 in TBS-tween containing 10% NSS and 3% BSA was applied for 45 
minutes, after which slides were rinsed with TBS-tween, treated with 3% H2O2 in TBS-tween 
for 25 minutes, rinsed and then incubated with streptavidin-conjugated HRP (Invitrogen) diluted 
1:200 in TBS-tween for 30 minutes. Development of the color was performed in custom 12-slide 
plastic containers (Antibody Amplifier™ containers, ProHisto, LLC, Columbia, SC, USA) by 
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applying Nova Red (Vector Laboratories, Inc.) for about 90 seconds followed by copious rinses 
with ddH2O, counterstaining with Harris’ hematoxylin (for 2 minutes), bluing with alkaline 
Scott’s water (for 1 minute), dehydration and coverslipping with Permount mounting medium 
(Sigma, St. Louis, MO, USA). 20 unique 10X fields on each slide (containing two lung sections 
each) were assessed for RSV antigen staining by counting positively-stained cells within 
bronchioles and alveoli.  
Collection of Bronchoalveolar Lavage Fluid (BALF) 
After the lungs of each lamb were removed, the right caudal lung lobe was excised and 
instilled with 5 mL of cold DMIM (42.5% Iscove's modified Dulbecco's medium, 7.5% glycerol, 
1% heat-inactivated FBS, 49% DMEM, and 5 μg/ml kanamycin sulfate) after which 1 mL of the 
resulting BAL fluid was placed on ice and spun down for 5 minutes in a centrifuge at 3,000 x g 
to pellet large debris. Approximately 800–850 μL of each supernatant was collected and then 
spun through 850 μL-capacity 0.45 μm Costar SPIN-X filter (microcentrifuge 15,600 x g) for 5 
minutes before being used in the standard infectious focus forming unit assay (FFU). 
Focus-Forming Unit (FFU) Assay 
Viral titers in bronchoalveolar lavage fluid (BALF) from the right lung caudal lobe were 
determined using an infectious focus assay (FFU). In brief, 200 µL of serially-diluted BALF 
samples were applied to HEp-2 cells grown to 70% confluence in 12-well culture plates (Fisher 
Scientific, Hanover Park, IL) in DMEM media (Mediatech, Inc., Manassas, VA) supplemented 
to 10% with heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA) and 50 
µg/mL kanamycin sulfate (Invitrogen/Life Technologies). Each sample was analyzed undiluted 
and at four additional serial-dilutions of 1:10, 1:100, 1:1,000 and 1:10,000 in duplicate. 
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Following a 48-hour incubation at 37°C, 5% CO2, the cells were fixed with cold 60% 
acetone/40% methanol solution for 1 minute. Overnight primary polyclonal goat anti-RSV (all 
antigens) antibody (EMD Millipore Corporation, Billerica, MA, USA) incubation was followed 
by washing and secondary antibody (Alexa Fluor® 488 F(ab’)2 fragment of rabbit anti-goat IgG 
(H+L), Molecular Probes/Life Technologies) incubation for 30 minutes. Plates were rinsed and 
inspected for the presence of fluorescing foci of infection using the FITC/GFP filter on an 
inverted fluorescence microscope (Olympus CKX41, Center Valley, PA). Five or more 
fluorescing cells were counted as single focal events. An average of 40 counts in a 1:10-diluted 
(duplicate) sample indicated an original BALF sample “titer” of 2,000 [40 counts x dilution of 10 
x 1,000 µL/mL]/200 µL assessed = 2,000 infectious focus-forming units/mL (FFU/mL). 
Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) for RSV in 
Bronchoalveolar Lavage Fluid 
Viral RNA was quantified by reverse transcription quantitative polymerase chain reaction 
(RT-qPCR) in BALF obtained from each animal at necropsy. BALF was obtained from the right 
caudal lung lobe of each animal (see section on BALF collection). Briefly, 100 μL of BALF was 
pipetted directly into 1 mL of TRIzol (Invitrogen/Life Technologies, Carlsbad, CA, USA) on ice, 
inverted to mix, and then transferred to -80°C for storage until RNA isolation and subsequent 
RT-qPCR. Upon thawing, each 1.1 mL sample was vortexed for 10 seconds and allowed to sit at 
room temperature for 10 minutes. RNA isolation from BALF samples continued as per 
manufacturer’s instructions. The resulting (non-visible) RNA pellets, were each dissolved in 100 
μL of nuclease-free water (Invitrogen/Life Technologies), vortexed thoroughly, microfuged 
briefly, warmed to 60°C for 3 minutes, vortexed for 5 seconds, microfuged briefly, then 80 μL of 
each was diluted 1:10 with a combination of 10 μL RNaseOUT™ (to 0.5 Units/ μL), and 710 μL 
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nuclease-free water, then stored at 4°C prior to RT-qPCR. RT-qPCR for RSV was then carried 
out as described above in the section: “Reverse transcription quantitative polymerase chain 
reaction (RT-qPCR) assessment of RSV and chemokine gene mRNA expression levels in lamb 
lung”. 
Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) Assessment of 
RSV and Chemokine Gene mRNA Expression Levels in Lamb Lung 
For each animal, tissue samples from right and left cranial, left middle and left caudal 
lung lobes (0.3–0.4 g of each lobe) were homogenized for total RNA isolation in TRIzol 
(Invitrogen) and previously described methods [26]. RNA was assessed for quantity and purity 
by spectrometry (Beckmann DU® 640B, Beckmann Coulter Inc., Brea, CA, USA) and all 
OD260nm/280nm values measured between 1.96 and 2.12. Agilent Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA, USA) analysis of RNA prior to DNase treatment consistently 
yielded RIN values ≥8.0 for all lamb lung RNA samples isolated this way [27]. Reverse 
transcription quantitative polymerase chain reaction (RT-qPCR) was performed using One-Step 
Fast qRT-PCR Kit master mix (Quanta, BioScience, Gaithersburg, MD, USA) in a GeneAmp 
5700 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA) and PREXCEL-Q 
for all set up calculations [29, 30]. Primer and probe sequences for all targets were designed with 
ABI Primer Express 2.0, and have been used previously [17, 26, 31]. Primers and hydrolysis 
probe for targeting M37 hRSV NP RNA were designed using ABI Primer Express version 2.0 
based on RSV accession number M74568. Thermocycling conditions were 5 minutes at 50°C; 30 
seconds at 95°C; and 45 cycles of 3 seconds at 95°C and 30 seconds at 60°C. Samples and 
standards were assessed in duplicate, and each target gene quantification cycle (Cq) value was 
converted to a relative quantity (Qr) based on each target’s standard curve using: Qr = EAMP(b-
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Cq), wherein “b” and “EAMP” are the y-intercept and exponential PCR amplification value, 
respectively. EAMP values were obtained from the slope (m) of each target standard curve by: 
EAMP = 10(-1/m), and all Qr values interpolated from standard curves were normalized to total 
lung RNA per RT-qPCR (0.784 ng RNA/μL for all reactions). No-RT control (NRC) reactions 
gave either no signal or generated Cq values greater than 13 cycles later than those in the 
corresponding RT-qPCR target reactions. 
Statistical Analysis 
Data were analyzed using SAS® software (SAS® inst. Cary, NC) with generalized linear 
mixed models (GLIMMIX), to compare changes in behavior frequencies across trial days and 
between control and inoculated lambs. Behavior frequencies were divided by the total number of 
observations for each lamb and subsequently analyzed. The statistical model included the fixed 
effects of trial day, treatment and the interaction of trial and treatment. Treatment nested within 
Pen was included as a random effect. P-value ≤0.05 was considered to be significant. 
Longitudinal quantitative data were analyzed using repeated measures analyses of variance 
(ANOVA) with SAS software, and a P-value ≤0.05 was considered to be significant. 
 
Results 
General Illness 
General illness signs were sparse and few for the RSV infected and non-infected groups. 
For the infected group, general illness signs were first observed on day 1 p.i. for lambs 8 and 9, 
which displayed general illness scores of 2 and 3, respectively (Table 1). Lamb 9 also had a fever 
of 104.8°F for day 1 p.i., before being euthanized on day 2 p.i. for seizing and having a fever of 
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107.0°F. This left lamb 8 by itself in group 4 with its neighboring group 5 to socialize with. 
There were no other general illness scores for the remaining days of the study for the infected 
group. For the non-infected group general illness signs were first observed on day 3 p.i. for lamb 
3, which had general illness score of 3. On day 4 p.i., lamb 3 had a general illness score of 2. No 
other general illness sings were observed for the non-infected group. 
Body Temperature 
For the most part, the non-infected group had higher mean body temperatures than the 
RSV infected group, with the exception of days 1 and 2 p.i (Figure 2). However, mean body 
temperature for both groups were only statically significant  at days 1 and 5 p.i. Mean body 
temperatures for the RSV infected group stayed within the normal limits of a newborn lamb’s 
body temperature of 102.0°C-103.0°F, except for days 6 and 8 p.i were body temperatures were 
above 103.0°F. In comparison to the infected group, mean body temperatures for the non-
infected group were above 103.0°F for days 1 through 8 p.i. 
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Figure 2. Mean body temperatures of RSV infected and non-infected (vehicle) groups. Mean 
body temperatures of RSV infected and non-infected (vehicle) lambs.  Rectal temperatures were 
measured daily using a digital thermometer beginning at day -1 through day 8 post treatment.  
Results are shown as mean ± standard error. 
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Looking at individual fevers in both groups, lambs 8, 10, and 12 in the infected group had 
1 to 2 days of sporadic fevers. Lamb 14 had the most days of fever (4, 5, 6, 8) p.i., followed by 
lambs 13 (6, 7, 8 days p.i.) and 11 (-1, 3, 4 days p.i.). Lambs in the non-infected group had fevers 
that were more prevalent and consecutive than the infected group, with all lambs having fevers at 
day 1 p.i., except for lambs 7 and 6, which had fevers on day -1 and 5 p.i., respectively. Lambs 3 
and 7 had fevers from days 1 through 8 p.i. Lamb 2 also had fevers for most days of the infection 
period (days 1 through 8 p.i.), except for day 5 p.i. Lambs 1 and 3 did have consecutive fevers 
from days 1 through 3 p.i, followed by two days of sporadic fever. Lambs 4 and 6 only had 3 
days of fever, with lamb 6 having sporadic days of fever and lamb 4 having fever on days 5, 6, 
and 8 p.i. 
Respiration Rates 
Auscultated mean respiratory rates for the infected group peaked at day 3 (53 bpm) and 
day 7 (57 bpm) p.i., in comparison to the non-infected group which only had one peak at day 1 
(55 bpm) p.i (Figure 3). At day 8 p.i., respiratory rates for both groups began to decrease. 
Between both groups, only day 1 p.i. was statistically significant.  
High respiration rates were observed infrequently for both groups, with lambs 13 and 14 
in the infected group having high respiration rates on days 7 (100 bpm) and 3 (80 bpm) p.i. Only 
lamb 2 in the non-infected group had high respiration rate on days 1 (120 bpm), 2 (80bpm), 4 (80 
bpm), and 5 (80bpm) p.i. Expiratory efforts were only observed for the infected group, for lambs 
13 and 14 on days 4 and 7 and 4 p.i., respectively.  
There were also bilateral harsh lung sounds in the infected group that were sporadic for 
lambs 10, 12, 13, beginning on day 4 and ending on day 8 p.i., Lamb 11 had bilateral harsh lung 
sounds throughout this period of the study (days 4-8 p.i.). For the non-infected group, bilateral 
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harsh lung sounds were also sporadic and were only present on days 4 and 8 p.i. for lambs 2 and 
1, respectively.  
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Figure 3. Respiratory rate assessment of RSV infected and non-infected groups. Respiratory rates 
were taken daily by auscultation using a stethoscope and breaths per minute (bpm) was 
calculated by counting the number of breaths in 15 seconds and multiplying it by 4. Results are 
shown as mean ± standard error. 
 
 
Behavioral Observations 
There was no statistical difference in locomotion, socialization, and feeding between both 
infected and non-infected groups. Contrary to our hypothesis, infected lambs spent significantly 
less time lying and more time standing than the non-infected lambs (Figure 4A and 4B). 
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Figure 4 (A, B) sickness behavior. Behavioral observations (feeding, locomotion, standing, 
laying, socialization) for the infected and non-infected groups were collected using instantaneous 
scan sampling every 10 minutes from video recordings of lambs that occurred between 6:30 and 
18:30 on days 0 through 7, relative to inoculation. All observations were collected by one trained 
researcher blinded to animal ID, treatment and trial day (intra-observer reliability was 98%). 
Behavior frequencies were summed for each trial day and subsequently analyzed. 
 
Gross and Microscopic Lung Lesions 
Gross lung lesions for the infected group were bilateral, evenly-distributed and 
characterized by multifocal to locally extensive dark plum-red, well demarcated foci of 
pulmonary consolidation which varied from moderate to severe; consistent with RSV infection in 
lambs as previously reported [16, 25, 26]. Lamb 11 had the highest percent total involvement of 
all lung lobe lesions, while lamb 8 had the lowest (Figure 5). 
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Figure 5.  Scoring of gross lesions caused by M37 hRSV infection in neonatal lambs. The 
percent total involvement of all lung lobe lesions was calculated by adding up estimated 
percentages of gross lesions given to each lung lobe and dividing by 7, which is the number of 
lung lobes present in lambs. Lamb 9 was euthanized at day 2 p.i. for having a high fever and 
seizing.  
 
Microscopic lesions for the infected group consisted mostly of consolidation, 
bronchits/bronchiolitis, peribronchial and perivacular lymphocyte infiltration, and to lesser 
extent neutrophilic inflammation and epithelial hyperplasia as previously has been described for 
day 8 p.i.[16]. Gross lesions overlapped with the severity of microscopic lesions for each lamb, 
except for lambs 8 and 11. Lamb 11 had the highest total percent involvent of lung lobe gross 
lesions (53.57%), but did not have the highest score of microscopic lesions. Lamb 8 had the 
lowest total percent involvement of lung lobe lesions (26.43%), but had the highest score of 
microscopic lesions. Also, the microscopic lesions observed for lamb 14 are characteristic of an 
early RSV infection (Figure 6). 
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Figure 6. Microscopic lung lesions severity score in M37 hRSV infected neonatal lambs. A 
histologic score was given by determining percent consolidation followed by conversion to an 
integer-based consolidation scale used by our laboratory previously [1]: 0% consolidation = 0; 
1%-9% consolidation = 1; 10%-39% consolidation = 2; 40%-69% consolidation = 3; 70%-100% 
consolidation = 4.  
Figure 9 continue: Group averages were calculated for alveolar and bronchiolar consolidation 
scores. In addition to the consolidation score, bronchitis, bronchiolitis, neutrophil infiltration, 
peribronchiolar and perivascular infiltration of lymphocytes, syncytial cell formation, and 
epithelial alterations were also scored. Results are indicated as mean ± standard error for each 
scored parameter. Lamb 9 was euthanized at day 2 p.i. for having a high fever and seizing. 
 
  Lambs 3, 6, and 7 in the non-infected group had gross lesions that were unilateral, and 
cranial ventral (right cranial and middle lung lobes being mostly affected), and were 
characterized by multifocal, locally extensive, firm, red-brown areas. These lesions are 
suggestive of a bacterial pneumonia and were not seen in the infected group. Other lesions in the 
non-infected group included, congestion and hemorrhage in all lobes of the left lung in lamb 5. 
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Both of these lesions were recorded and were not sampled for attaining experimental endpoints. 
Microscopically, only lamb 7 had areas of consolidation with neutrophilic inflammation. 
Viral Titers, Viral RNA Replication Levels, and Viral Antigen Expression 
The viral titers and viral RNA in BALF and lung tissue, as well as viral antigen 
expression coincided with each other, but did not overlap with the gross or microscopic lesions. 
For instance, lamb 14 had the highest viral titers (5.4 log10 FFU/mL), viral RNA levels in BALF 
(2.1 log10 RNA copies/mL) and lung tissue (2.9 log10
 
copies/ mg lung tissue), and viral antigen 
expression in both bronchiolar and alveolar staining (Table 5 and Figure 7); however, lamb 14 
did not have the highest gross viral lung lesions. As previously mentioned, lamb 14 also had 
microscopic lesions associated with early RSV infection. Another example is lamb 11, which 
had the highest gross viral lung lesions, with no detectable cultivable viral titers, and had the 
lowest viral RNA levels in BALF (6.63 log10 RNA copies/mL) and lung tissue (4.38 log10 
copies/ mg lung tissue),  and viral antigen expression in bronchioles.  
Table 5. Quantification of RSV replication via infectious focus assay and RT-qPCR in 
lambs inoculated with M37 hRSV  
   
Lamb 
# 
BALF Viral 
Culture (log
10
 
FFU/mL) 
BALF RT-qPCR (log
10
 
M37 RNA copies/mL) 
Lung Tissue RT-
qPCR (log
10
 M37 
RNA copies/mg lung) 
8 2.68 7.33 5.93 
9 0.00* 0.00* 0.00* 
10 3.19 7.33 6.16 
11 **BDL 6.63 4.38 
12 1.60 7.15 5.71 
13 2.37 7.17 5.54 
14 5.36 9.31 7.46 
* Lamb 9 was euthanized at day 2 p.i. for having a high fever and seizing. 
** BDL= Below Detection Limit 
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Figure 7. Scoring of RSV antigen expression in infected and non-infected groups. 
Immunohistochemistry was used to detect viral antigens using an all-antigens polyclonal 
antibody for  RSV. Immunohistochemistry and scoring of RSV antigen expression in lambs 
inoculated with M37 hRSV. Immunohistochemistry was used to detect viral antigen using an all-
antigens polyclonal antibody for RSV. The mean number of virally-infected bronchi/bronchioles 
and alveoli per field was counted for each day of necropsy. 
 
Chemokine and Cytokine Expression of Lung Tissue 
Lung cytokine and chemokine mRNA expression levels were quantified by RT-qPCR 
and demonstrated varying patterns for the infected and non-infected groups as previously 
reported for day 8 p.i [16] (Figure 8).  
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Figure 8. Lung chemokine mRNA expression assessed by RT-qPCR in lambs inoculated with 
M37 hRSV. Lung tissue obtained from each animal was evaluated for the following mRNA 
targets: monocyte chemotactic protein 1 alpha (MCP-1α), interferon beta (IFN-β), interferon 
gamma (IFN-γ), programmed cell death 1 ligand 1 (PD-L1), and regulated on activation normal 
T-cell expressed and secreted (RANTES) and Clara cell secretory protein (CC10). Mean relative 
mRNA expression was calculated for each target with respect to each day of necropsy. Relative 
mRNA expression means:  relative to the total amount of RNA loaded per reaction (which is 
kept constant) and relative to the values established by the standard curves for each target. 
 
Discussion 
The aim of this study was to determine the clinical symptomology and sickness behavior 
of RSV infected lambs. 
Eliminating the heavy sampling schedule from this study still proved to be difficult when 
determining the clinical signs and sickness behavior of RSV infected lambs, as non-RSV clinical 
signs of tremors and lameness affecting both groups, as well as bacterial pneumonias in the non-
infected group, and variability in RSV infection were present, which confounded the results. 
Bacterial infections are an inherent problem of the hRSV infection neonatal lamb model, and as 
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long as they are present, interpretation of clinical data and lamb behaviors should be done with 
caution when drawing conclusions. 
Considering that both groups of lambs had fevers, high respiration rates, bilateral harsh 
lung sounds, and non-specific RSV clinical sings of lameness and tremors, it’s evident that both 
groups were infected with a pathogen other than RSV. These non-specific RSV clinical signs are 
suggestive of a systemic bacterial infection. Eventhough, all lambs receive a daily intramuscular 
antibiotic, bacterial infections still remain a problem when dealing with colostrum free neonatal 
lambs.  This brings up the importance of requiring bacterial culture and sensitivity for all lambs 
involved in the study. This would help with pattering common pathogens that the lambs succumb 
to, and hopefully be able to provide more effective antibiotics that could prevent bacterial 
infections, that in the long run would eliminate unwanted clinical signs and increase the survival 
rate of lambs to the end of the study.  
           Besides the non-RSV clinical signs present in both groups, necropsy findings of the non-
infected group also had three lambs (3, 5, 7) with lung lesions that were suggestive of  a bacterial 
pneumonia, as well as lamb 6 having congestion and hemorrhage in the lungs. Histopathology, 
only confirmed a bacterial pneumonia for lamb 7, which had lung consolidation with 
neutrophilic inflammation. In previous studies (not published), where lambs have died from non-
RSV clinical signs and have been submitted to the veterinary diagnostic lab, bacteria culture has 
yielded for the most part Escherichia coli. This was also true for lamb 9, which was euthanized 
for having a fever and seizing on day 2 p.i. Gross and microscopic findings for lamb 9 were 
consistent with a meningoencephalitis and a mild interstitial pneumonia. Bacterial culture was 
done and lesions were attributed to a systemic bacterial infection with Escherichia coli. 
Furtheremore, along with bacterial culture and sensitivity, all lambs should have full necropsies, 
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with histopathology to not only confirm secondary bacterial infections and RSV infection, but 
also determine if all lambs where infected with RSV at the same time.  
Overall, clinical signs and sickness behavior where present in both groups, beginning 
with geneal illness signs that were sparse for both infected and non-infected lambs. Fevers were 
also present in both groups with the lambs in the non-infected group having more prevelant and 
consecutive fevers. The respiratory rates where variable and unpredictable. High respiration rates 
were present infrequently in both groups, with bilateral harsh lung sounds being more prominent, 
but sporadic in the infected group. There was no statistical difference in heart rates, body 
weights, and milk consumption between both groups.  
Expiratory efforts were the only clinical sign observed in the infected group that was not 
seen in the non-infected group. There was no wheezing observed for either group. As previously 
mentioned, the only clinical sign that has been observed the most in lambs as a significant 
clinical marker to monitor for RSV disease is expiratory effort [16, 25-27]. Even though only 
two lambs in the infected group had expiratory efforts, our hypothesis was that expiratory efforts 
and wheezing would be more apparent by removing the heavy sampling schedule that previous 
lamb studies included. It’s not certain if expiratory efforts and wheezing may have been 
exacerbated in previous lamb studies by the stress of handling lambs for blood withdrawals, drug 
delivery, vital parameters, ect., or by secondary bacterial pneumonias that are an inherent 
problem of the RSV neonatal lamb model, making these clinical signs more apparent [16].  
Behavioral observations indicated that the infected group spent significantly less time 
lying and more time standing than the non-infected group. It’s counterintuitive to the sickness 
response that sick animals would be standing more rather than lying and conserving energy. A 
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possible explanation for this behavior is that sick animals seek heat to faciliate fever during the 
immune response to an infection [7].  
From the gross viral lung lesions, it appeared that all lambs had been infected with RSV. 
However, not all lambs where infected at the same time because the microscopic lesions, 
specifically for lamb 14, where characteristic of an early RSV infection. Interestingly enough, 
lamb 14 had the highest viral titers, viral RNA levels in BALF and lung tissue, and viral antigen 
expression in bronchioles and alveoli. From previous studies, viral titers and viral RNA levels in 
BALF and in lung tissue are decresing by day 8 p.i. [16]. Due to the lambs not being infected 
with RSV at the same time, the gross and microscopic lesions did not overlap with each other or 
with the viral endpoints as previous studies have reported [16]. Moreover, gross lesions should 
not be look at solely to determine lamb infectivity, but rather together with histopathology and 
viral endpoints to determine if lambs are infected with RSV at the same time.  
Depending on the time course of RSV infection and diagnosis, infants can display a 
variety of clinical symptoms that make it difficult to assess the progression of clinical sings. For 
the most part, RSV clinical signs in infants and young children are variable, but include 
wheezing, crackles, rhonchi, tachypnea, nasal flaring, fever, coughing, and intercostal muscle 
retractions. These symptoms can be associated with bronchiolitis due RSV and/or bacterial 
pneumonias [32, 33].  
Future lamb studies should make an effort to identify and prevent secondary or 
opportunistic pathogens in RSV infected and non-infected lambs by doing full necropsies and 
bacterial culture and sensitivity, as well as viral and bacterial diagnostics to solely demonstrate 
RSV infection.  
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CHAPTER 5.    GENERAL CONCLUSION 
Kinetics of RSV M37 Strain  
In order to utilize the lamb model for therapeutic and vaccine studies, the viral kinetics of 
RSV M37 strain needed to be first characterize. This study demonstrated that RSV M37 
replication in the lower airways of newborn lambs is robust with peak replication on day 3 and 
sustained until day 6. The viral kinetics coincided with that of lung gross viral and 
histopathological lesions, as well as viral antigen expression, and respiratory distress that 
included expiratory effort and wheezing. The chemokine and cytokine profile, specifically IL-8 
and IFN-γ, also overlapped with the expiremtal endpoints discussed above. Peak expression of 
IL-8 was present at day 6 post-infection and coincided with peak neutrophil influx in the lungs of 
RSV-infected lambs which indicates that the increased chemokine expression contributed to 
neutrophil infiltration into the site of intense RSV infection. IFN-γ expression was maximal at 
day 8 post-infection at a time when peak lymphocyte lung infiltration was noted, which suggests 
that RSV infection in neonatal lambs results in an initial innate inflammatory response, the peak 
of which coincides to that of peak disease, and is characterised by IL-8 secretion and neutrophil 
influx. A suppressed lymphocyte function and increased plasma IL-8 levels were shown to be 
markers of severe disease in RSV bronchiolitis [1]. 
 These findings, along with the similarities of lamb lung to those of infants in terms of 
alveolar development, airway branching and epithelium, susceptibility to human RSV strains, 
lesion characteristics (bronchiolitis), lung size, clinical parameters, and immunity, further 
establish the neonatal lamb as a model with key features that mimic RSV infection in infants. 
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Efficacy Evaluation of ALX-0171  
The use of neonatal lambs to model RSV infection in human infants has provided a 
valuable tool to assess vaccines and antiviral drug safety and efficacy. A trivalent Nanobody, 
ALX-0171, targeting the RSV F-protein was developed by Ablynx and its therapeutic potential 
was evaluated in newborn lambs infected with RSV M37 strain, following daily ALX-0171 
nebulization for 3 or 5 consecutive days. When compared to placebo-treated lambs ALX-0171 
treated lambs had a >10,000-fold decline in cultivatable virus, markedly reduced lung viral 
antigen expression, reduced lung viral lesions and reduced histological changes. Clinical signs 
were reduced for ALX-0171 treated RSV infected lambs. Overall, ALX-0171 was well-tolerated 
in RSV infected newborn lambs and results are indicative of the therapeutic potential of ALX-
0171 in infants. 
RSV Clinical Signs and Sickness Behavior 
To determine the clinical response of the therapeutic drugs or vaccines tested in the RSV 
infected lamb model, the clinical signs and sickness behavior also need to be fully characterized. 
This study solely looked at clinical signs and sickness behavior through clinical data and video 
recording of lamb behaviors, without the heavy sampling schedule of previous studies. The 
results of the clinical signs and sickness behavior were confounded by non-RSV clinical signs of 
tremors and lameness affecting both groups, as well as bacterial pneumonias in the non-infected 
group, and variability in RSV infection. Taking into account these non-RSV clinical signs, it’s 
evident that both groups of lambs were infected with a pathogen other than RSV. It’s not certain 
to what degree of impact these clinical signs had on the sickness behavior, but overall, RSV 
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infected lambs spent significantly less time lying and more time standing than the non-infected 
lambs. As far as the clinical signs, the only clinical sign that was not associated with the non-
infected group was expiratory efforts, which were only seen in two lambs. Expiratory efforts in 
previous studies have been the most consistent clinical sign to monitor RSV disease [2, 3, 4]. 
However, the possibility of a bacterial pneumonia leading expiratory efforts should not be ruled 
out.  In this study, only the non-infected lambs had bacterial pneumonias and no expiratory 
efforts were observed. Considering that not all infected lambs were infected with RSV at the 
same time, the clinical signs and sickness behavior were further confounded and did not overlap 
with the gross and histopathological lesions, and viral endpoints observed. 
Bacterial infections are an inherent problem of the hRSV infection neonatal lamb model, 
and as long as they are present, interpretation of clinical data and lamb behaviors should be done 
with caution when drawing conclusions.   
Future Lamb Studies  
If the lamb model is to continue to be used in the evaluation of therapeutics and vaccines, 
future lamb studies should make an effort to identify and prevent secondary or opportunistic 
pathogens in RSV infected and non-infected lambs by doing full necropsies and bacterial culture 
and sensitivity, as well as viral and bacterial diagnostics to solely demonstrate RSV infection. If 
lambs are infected with other than hRSV, caution should be used when making interpretations or 
drawing conclusions.  
Regarding the variability of infectivty in lambs, it might be worth while to characterize 
the viremia in serum to have a different experimental endpoint to follow the viral kinetics in 
lambs. This experimental endpoint can also be used to further corroborate the clinical signs and 
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sickness behavior for the RSV infected group. The cytokine and chemokine profile should also 
include IL-1, IL-6, and TNF-α for the RSV infected lambs, which are the primary cytokines for 
the sickness behavior.Along with measuring the virus in serum, the antibody profile of IgG, IgM, 
and IgA against RSV should be investigated not only in serum, but in also in BALF and lung 
tissue to further characterized the immune respose in the lamb model. It has been reported that 
nasal IgA from experimentally infected adults with hRSV is the best predictor of RSV protection 
[5]. A lack of virus specific IgA memory cells in nasal samples has been shown to contribute to 
reinfection [5]. Virus specific IgA memory cells along with IgG and IgM memory cells should 
also be characterized in the lamb model.   
Our lamb studies using RSV M37 have only gone up to day 8 p.i. It would be interesting 
to follow the histology, cytokine and chemokine profile, and viral endpoints passed day 8 p.i. to 
get an idea of the repair process. This may elude to the high risk factor to asthma that infants 
experience after long term severe RSV disease [6]. Extending the period of the lamb studies 
would also allow the investigation of reinfection as commonly occurs in humans [7, 8]. 
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